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ABSTRACT OF THE DISSERTATION 
GENETIC MARKERS, BIRTH CHARACTERISTICS, AND  
CHILDHOOD LEUKEMIA RISK 
by 
Amy Kennedy 
Florida International University, 2013 
Miami, Florida 
Professor Mehmet T. Dorak, Major Professor 
The cause for childhood acute lymphoblastic leukemia (ALL) remains unknown, 
but male gender is a risk factor, and among ethnicities, Hispanics have the highest risk. In 
this dissertation, we explored correlations among genetic polymorphisms, birth 
characteristics, and the risk of childhood ALL in a multi-ethnic sample in 161 cases and 
231 controls recruited contemporaneously (2007-2012) in Houston, TX. We first 
examined three lymphoma risk markers, since lymphoma and ALL both stem from 
lymphoid cells. Of these, rs2395185 showed a risk association in non-Hispanic White 
males (OR=2.8, P=0.02; Pinteraction=0.03 for gender), but not in Hispanics. We verified 
previously known risk associations to validate the case-control sample. Mutations of HFE 
(C282Y, H63D) were genotyped to test whether iron-regulatory gene (IRG) variants 
known to elevate iron levels increase childhood ALL risk. Being positive for either 
polymorphism yielded only a modestly elevated OR in males, which increased to 2.96 
(P=0.01) in the presence of a particular transferrin receptor (TFRC) genotype for 
rs3817672 (Pinteraction=0.04). SNP rs3817672 itself showed an ethnicity-specific 
association (Pinteraction=0.02 for ethnicity). We then examined additional IRG SNPs 
vii 
 
(rs422982, rs855791, rs733655), which showed risk associations in males (ORs=1.52 to 
2.60). A polygenic model based on the number of polymorphic alleles in five IRG SNPs 
revealed a linear increase in risk (OR=2.00 per incremental change; P=0.002). Having 
three or more alleles compared with none was associated with increased risk in males 
(OR=4.12; P=0.004). Significant risk associations with childhood ALL was found with 
birth length (OR=1.18 per inch, P=0.04), high birth weight (>4,000g) (OR=1.93, 
P=0.01), and with gestational age (OR=1.10 per week, P=0.04). We observed a negative 
correlation between HFE SNP rs9366637 and gestational age (P=0.005), again, stronger 
in males (P=0.001) and interacting with TFRC (P<0.001; Pinteraction=0.05). Our results 
showed that (i) ALL risk markers do not show universal associations across ethnicities or 
between genders, (ii) IRG SNPs modify ALL risk presumably by their effects on iron 
levels, (iii) a negative correlation between an HFE SNP and gestational age exists, which 
implicates an iron-related mechanism. The results suggest that currently unregulated 
supplemental iron intake may have implications on childhood ALL development.  
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CHAPTER I 
INTRODUCTION  
Cancer is the second leading cause of death among children ages 1-14, surpassed 
only by accidents [1]. Despite making up only a small percentage of the total cancer cases 
in the United States, approximately 1 in 100 new cancers is a childhood cancer, and the 
number of childhood cancer cases has increased gradually over the past few decades. 
Acute lymphoblastic leukemia (ALL) is the most common leukemia among children 
[2,3]. There are approximately 30-45 children per 1,000,000 affected by this malignancy 
annually [4], making up 80% of all childhood leukemias [4,5], with a peak incidence 
occurring between the ages of 2 and 5 [6]. The racial/ethnic variation in the incidence of 
childhood ALL is well established [4,7]. The highest incidence rates are among Hispanic 
populations [8-10], followed by non-Hispanic Whites, Asians, and then Blacks [4].  
ALL is typically characterized by an excess amount of lymphoblasts. Instead of 
maturing into functional lymphocytes, an abundance of stem cells develop into 
lymphoblasts, which are immature, malignant white blood cells [11]. These non-
functional leukemia cells accumulate quickly in the blood and bone marrow, reducing the 
effectiveness of healthy bloods cells in fighting infection, and eventual spread to other 
organs [12]. The most common subtype of ALL is B-cell precursor (BCP) ALL, 
accounting for 70% of childhood ALL [3]. 
Great improvements have been made in the treatment of ALL. In the 1960s, the 5-
year survival rate was less than 10% [13]. This rate has continually increased from 77% 
in 1985-1994 [13] to 87.5% in 2000-2004, and is now estimated to be greater than 90% 
[14]. The increase in survival rates is due to the combination of better diagnostics through 
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molecular and microarray testing, and better treatments individualized to patients [15]. 
Despite the improving prognosis, the incident rate of ALL has increased annually over 
the past few decades, and the exact cause of the disease remains unknown in more than 
90% of the cases [15]. Survivors of childhood leukemia also have an increased risk for 
other malignancies later in life, and almost two thirds of all pediatric cancer survivors 
suffer from at least one permanent side effect from their treatment [16], which 
emphasizes the need for prevention methods. 
There are a few well established risk factors for childhood ALL, including race, 
sex, age peak, maternal age, and certain genetic disorders, including Down Syndrome, 
[17-22], but the exact cause is unknown in more than 90% of the cases [15,19]. Table I 
lists the established, suggestive, and controversial risk factors associated with childhood 
ALL. Birth weight has been recognized consistently as a risk factor for childhood ALL 
[23-36]. Less than 5% of diagnosed cases are associated solely with genetic defects [19], 
therefore many researchers are exploring environmental links to the disease. Ionizing 
radiation can increase the risk for ALL [28], although the relationship is more established 
with acute myeloid leukemia (AML). 
It is likely that increased risk for childhood ALL involves the combination of 
environmental insults and genetic predisposition [37].  There have been several genome 
wide association studies (GWAS) conducted to identify risk variants for childhood ALL 
[38-40].  Table II lists the polymorphisms found to be statistically significant with 
childhood ALL risk in GWAS. 
Candidate gene studies have also yielded many risk associations [38], although 
many have yet to be replicated. Variants located in the iron-related hemochromatosis 
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(HFE) gene, rs1800562 (C282Y) and rs1799945 (H63D), have been associated with an 
increase in birth weight and childhood ALL risk, in males only [35,41-44]. These two 
variants are the major contributors to hereditary hemochromatosis (HH), an inherited 
disorder causing iron overload, which may progress to cell and tissue damage [45].  
Excess iron can cause cell stress and oxidative damage, and has been shown to increase 
susceptibility to cancer [46-49]. Male carriers of the variants of the HFE gene in 
particular have been shown to have an increased risk for numerous neoplasms [50]. The 
biological plausibility behind excess iron being a risk factor for childhood ALL is one 
worth pursuing, for both population health benefits and for scientific advancements. 
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Table I. Risk factors for childhood acute lymphoblastic leukemia 
Established Suggestive Controversial 
Sex Maternal reproductive history Maternal drug use 
Age peak Maternal alcohol use Exposure to nonionizing radiation 
Race Maternal diet Parental chemical exposure 
Birth weight Miscarriage history Household exposure to pesticides 
Down syndrome Advanced maternal age Parental smoking: prior and during pregnancy 
Genetic disorders Being the first-born or only child 
 
Ionizing radiation Post-natal use of chloramphenicol 
Sibling with leukemia, 
brain tumor or Down 
syndrome  
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Table II. Genetic associations with childhood leukemia risk previously established in 
genome wide association studies* 
 
SNP PMID** Sample population Chromosome nucleotide position Reported gene 
rs11978267 19684603 European ancestry chr7: 50466304 IKZF1, DDC 
rs11155133 19684603 European ancestry chr6: 141169825 Intergenic 
rs9290663 19684603 European ancestry chr3: 178429939 KCNMB2 
rs12621643 19684603 European ancestry chr2: 223917983 KCNE4 
rs2191566 19684603 European ancestry chr19: 44511389 ZNF230 
rs1879352 19684603 European ancestry chr18: 2498054 Intergenic 
rs2089222 19684603 European ancestry chr12: 117002658 KRTHB5 
rs10849033 19684603 European ancestry chr12: 4425122 C12orf5 
rs10821936 19684603 European ancestry chr10: 63723577 ARID5B 
rs563507 19684603 European ancestry chr10: 34817988 PARD3 
rs7554607 19684603 European ancestry chr1: 237266603 RYR2 
rs10873876 19684603 European ancestry chr1: 76772328 SIAT7C 
rs6428370 19684603 European ancestry chr1: 196844593 Intergenic 
rs1881797 19684603 European ancestry chr1: 247689532 OR2C3 
rs4132601 19684604 European ancestry chr7: 50470604 IKZF1 
rs2239633 19684604 European ancestry chr14: 23589057 CEBPE 
rs7089424 19684604 European ancestry chr10: 63752159 ARID5B 
rs6140264 20189245 Korean chr20: 7376354 HAO1 
rs9388856, 
rs9388857, 
rs1360756 
20189245 Korean chr6: 131148863 EPB41L2 
rs3776932 20189245 Korean chr5: 109185988 MAN2A1 
rs12105972 20189245 Korean chr2: 76648560 C2orf3 
rs920590 22076464 European ancestry chr8: 19651161 INTS10 
rs7738636 22076464 European ancestry chr6: 77789808 Intergenic 
rs282708 22076464 European ancestry chr4: 59503726 Intergenic 
rs17505102 22076464 European ancestry chr3: 189401776 TP63 
rs17505102 22076464 European ancestry chr3: 189401776 TP63 
rs207954 22076464 European ancestry chr15: 92657373 SLCO3A1 
rs7156960 22076464 European ancestry chr14: 76703351 C14orf118 
rs7156960 22076464 European ancestry chr14: 76703351 C14orf118 
rs1945213 22076464 European ancestry chr11: 56175671 OR8U8 
rs1945213 22076464 European ancestry chr11: 56175671 OR8U8 
rs3942852 22076464 European ancestry chr11: 48115089 PTPRJ 
rs17837497 23007406 Mixed chr7: 139702593 TBXAS1 
rs1496766 23007406 Mixed Cchr7: 78331465 MAGI2 
rs17079534 23007406 Mixed chr3: 39847072 MYRIP 
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Table II continued… 
 
 
*Hindorff LA, MacArthur J (European Bioinformatics Institute), Morales J (European Bioinformatics 
Institute), Junkins HA, Hall PN, Klemm AK, and Manolio TA. A Catalog of Published Genome-Wide 
Association Studies. Available at: www.genome.gov/gwastudies. Accessed September 10, 2013. 
  
**PubMed identifier number 
SNP PMID** Sample population Chromosome nucleotide position Reported gene 
rs10170236 23007406 Mixed chr2: 150457624 LOC642340 
rs9958208 23007406 Mixed chr18: 40591084 RIT2 
rs7578361 23007406 Mixed chr2: 150397218 Intergenic 
rs7142143 23007406 Mixed chr14: 51403531 PYGL 
rs41322152 23007406 Mixed chr10: 72040805 NPFFR1 
rs6683977 23007406 Mixed chr1: 66769100 PDE4B 
rs546784 23007406 Mixed chr1: 66762466 PDE4B 
rs6964969 23512250 European, African American,  Hispanic  chr7: 50473251 
IKZF1,DDC, 
GRB10 
rs4982731 23512250 European, African American,  Hispanic  chr14: 23585333 CEBPE 
rs10821936 23512250 European, African American,  Hispanic  chr10: 63723577 ARID5B 
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CHAPTER II 
 
HYPOTHESIS AND SPECIFIC AIMS 
 The purpose of this dissertation project is to explore the correlations among 
genetic polymorphisms, birth characteristics, and the risk of childhood ALL. It is known 
that gender is a risk factor for childhood ALL, with males having greater risk, and 
Hispanics have the highest risk of all ethnicities. We hypothesize that risk markers may 
not be universal for both genders and across ethnicities. We aim to exploit this 
differential to obtain etiologic clues for the development of childhood ALL. Another 
focal point is to test the hypothesis that iron-regulatory gene (IRG) variants known to 
elevate iron levels increase childhood ALL risk. Iron, which is necessary for cell division 
and fetal growth, has been shown to increase birth weight and susceptibility to cancer 
when found in excess. This research will seek correlations between genotypes (IRG 
variants) and phenotypes (birth characteristics and leukemia) to determine whether 
genotypes and their combinations associated with birth characteristics also modify the 
risk for leukemia.  
In order to test these hypotheses, the following specific aims will be explored: 
Aim 1) to genotype previously reported childhood ALL risk markers to validate the case-
control sample used in this project for the first time; 
Aim 2) to genotype lymphoma risk markers, since lymphoma and ALL both stem from 
lymphoid cells, for their correlations with childhood ALL risk and birth characteristics; 
Aim 3) to genotype iron-regulatory gene polymorphisms, some known to increase iron 
levels, for their correlations with childhood ALL risk and birth characteristics 
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Aim 4) to examine effect modification by race/ethnicity and gender in childhood ALL by 
stratified statistical analysis 
 Findings of this study may indicate that genetic risk markers are not universal for 
both genders and across ethnicities, and may be an important consideration in future 
genetic association studies. It will also provide evidence for or against the idea that iron 
excess mediated by genetic variants contribute to childhood ALL risk. If our hypothesis 
is confirmed, educating the public on lifestyle modifications for preventive measures 
such as controlled iron supplementation during pregnancy and avoidance from excessive 
consumption of iron-rich food could reduce the risk of leukemia in children.   
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CHAPTER III 
HEREDITARY HEMOCHROMATOSIS GENE (HFE) POLYMORPHISMS AND 
ASSOCIATIONS WITH DISEASE SUSCEPTIBILITY 
 
Abstract 
The implication of excess iron in cancer and disease susceptibility has long been 
recognized. The increase in oxidative stress due to an overload of the transition metal is 
believed to be the reason for its harmful effects on the body. The hemochromatosis 
(HFE) gene is known to be involved in iron regulation, and mutations to the gene can 
have negative effects on certain health conditions. In this review, we discuss the role iron 
has in the body, and examine what impact HFE gene polymorphisms have on disease 
susceptibility, focusing on childhood leukemia. PubMed was searched using the 
following key words: HFE or hemochromatosis gene with disease susceptibility, 
polymorphisms, cancer, leukemia, variants, or disease association. The mechanisms 
behind the disease associations are also explored. 
Role of iron 
Iron is a necessary element required for oxygen transport, DNA synthesis, and is 
involved in cell proliferation and fetal growth [1-4]. Iron is capable of donating and 
accepting an electron, converting from ferrous (Fe2+) to ferric (Fe3+), which makes it 
useful in metabolic reactions, but also potentially harmful to the body. Iron generates free 
radicals when abundant and not tightly bound, which can lead to cell damage. 
In humans, iron is found in heme proteins and in ferritin, an iron storage protein 
[5]. Iron is most commonly stored in the liver, spleen, and in bone marrow [6]. 
Circulating plasma iron is typically bound to one of the two binding sites on the protein 
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transferrin (TF) in healthy individuals. Cellular uptake of iron is dependent on the 
number of transferrin receptors (TFRCs) [5]. When cells are in need of iron, there is an 
increase in transcription of TFRC, and it is found greater numbers, therefore more 
receptors available for the TF-iron complex to bind and become internalized [5]. The 
opposite occurs when intracellular iron levels are high, in that transcription of TFRC 
mRNA is decreased, and therefore there are a reduced number of receptors available [5]. 
Intracellular iron is used for both ferritin and hemoglobin production, the protein found in 
red blood cells responsible for carrying oxygen throughout the body. 
Health issues may arise when either too little or too much iron is stored and 
absorbed in the body. Iron deficiency, commonly referred to as iron anemia, has been 
extensively researched and is a common condition. In individuals with iron anemia, 
TFRC production is typically increased, while ferritin production is decreased. The lack 
of iron can lead to a wide range of adverse health outcomes [7]. Iron overload has not 
been studied as extensively until recently, and is underestimated and underdiagnosed by 
physicians. The primary reasons behind iron overload include: 1) excessive intake of iron 
through intestinal absorption, 2) parenteral iron (intravenously or intramuscular), 3) 
inhaled iron, 4) release of stored iron into blood plasma, 5) the reduction of normal 
menstrual excretion of iron in premenopausal women, and 6) the lack of transferrin or 
lactoferrin protein [8]. When found in excess, iron can induce cell stress and oxidative 
damage due to the increase in free radicals [3,9]. With the depletion of antioxidants, 
DNA damage can progress cancer development or worsen symptoms of an inherited 
disease [10]. The role of iron in cancer and disease progression has been widely studied 
[9], yet the genetics behind iron overload is still not fully understood. The 
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hemochromatosis gene (HFE) encodes for a protein involved in iron regulation, and its 
mutations may increase the risk of developing numerous cancers.   
HFE gene 
The HFE (high iron FE) gene is located at 6p21.3, the short arm of chromosome 6 
at position 21.3, and is surrounded by histone genes at both ends. The gene is 
approximately 10kb in size, and has at least eleven alternative transcripts consisting of 
four to seven exons, all which encode a distinct domain of the protein [11]. The gene 
encodes for a 321 amino acid mature transmembrane protein product that is similar in 
structure to HLA Class I molecules, with two alpha and beta chains, although it is not 
involved in antigen presentation [11,12]. It was originally named HLA-H because of the 
similarities with other HLA genes.  
The HFE protein is expressed on cell surfaces in most tissues, but found most in 
the liver and small intestine [11], where iron absorption, transport, and storage takes 
place. HFE is also expressed on the apical plasma membrane of the syncytiotrophoblasts, 
which suggests it is the protein which regulates iron transport from the mother to the 
fetus [9]. Genome-wide association studies (GWAS) looking at hematological parameters 
such as serum markers of iron status have found significant associations with SNPs in the 
HFE gene. A list of the traits showing statistical significance with variants in the HFE 
gene is found in Table I. 
Although not clearly understood, the HFE protein is involved in iron homeostasis 
regulation, controlling iron uptake by interacting with transferrin receptor (TFRC) and 
hepcidin (HAMP) [13]. The main function of HFE is to regulate mucosal iron transfer in 
interaction with TFRC, mainly in the intestinal mucosa (iron absorption) and in the 
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placenta (materno-fetal iron transfer). Animal studies first discovered high levels of 
saturated serum transferrin and excessive iron buildup in the liver in HFE-deficient mice 
[14]. The high iron levels in the hepatocytes of HFE-deficient mice are similar in 
histopathology to humans with hereditary hemochromatosis, suggesting that HFE is in 
control of iron homeostasis [9]. Transferrin receptors allow iron intake into the cell when 
iron concentrations are low by binding with iron-bound transferrin molecules. When iron 
levels are adequate and pH conditions are neutral, the HFE protein binds to the TFRC 
complex, reducing cellular iron uptake [12]. The hormone hepcidin is a negative 
regulator of iron absorption that determines how much iron will be stored and released 
[15]. HFE is speculated to regulate hepcidin by keeping production levels high when 
there is enough iron inside the cell, ensuring that the body will not absorb or store too 
much iron [15,16].  
The interactions between HFE and TFRC have been observed previously in both 
adult cancers [17] and in childhood acute lymphoblastic leukemia [18]. In the study 
conducted by Beckman et al., variants of HFE and TFRC genes on their own were not 
associated with breast, colorectal, or multiple myeloma, but their genotype combinations 
were significantly different between controls and cases [17]. It is speculated that the 
carcinogenic effect may somehow be amplified with the combination of both gene 
variants, and be dependent on increased iron uptake [17]. Normal, wild-type HFE protein 
is able to bind to transferrin receptors, reducing the affinity of TF, therefore controlling 
iron homeostasis. When HFE is mutated with the C282Y mutation, this binding is unable 
to occur, therefore allowing TF to bind to the receptors, and iron absorption to be 
uncontrolled. Mutations to the HFE gene disrupt iron homeostasis by causing increased 
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iron levels, which can lead to many negative health conditions, including hereditary 
hemochromatosis (HH). 
HFE variants 
 Since the discovery of the HFE gene in 1996, many single nucleotide 
polymorphisms (SNPs) have been identified [19,20]. Information describing the most 
popular SNPs can be found in Table II. The two originally discovered missense 
mutations, rs1800562 (C282Y) and rs1799945 (H63D), account for most of the disease 
associations with HFE.  
C282Y is the result of a point mutation in the coding sequence (exon 4) of the 
gene, with a guanine-to-adenine transition at nucleotide 845. This alters the production of 
the amino acid in position 282, changing it from cysteine to tyrosine [21]. This mutation 
is the most deleterious, as the cysteine residue is highly conserved, and the protein is no 
longer able to bind properly to TFRC when altered. The transferrin molecule is then able 
to bind to the TFRC with high affinity, and iron is released [22]. The frequency of C282Y 
in the United States is estimated to be around 6% in non-Hispanic Whites [23]. The 
C282Y mutation appeared more than 2000 years ago and is now associated with a 
particular haplotype in European populations, and is not found or found in low allele 
frequencies in other populations [24]. Two copies of the C282Y mutation is found in 
approximately 90% of patients with hereditary hemochromatosis (HH), an autosomal 
recessive disorder causing iron overload [25]. 
The second most common HH associated variant is the H63D mutation, which is 
a result of guanine replacing cytosine at nucleotide 187, causing the amino acid in 
position 63 to change from aspartate to histidine. This mutation only shows symptoms of 
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iron overload when the individual also has a copy of the C282Y mutation on the other 
chromosome, and symptoms are typically mild [25]. The variant protein is still able to 
bind to TFRC, although it is unable to reduce the affinity of transferrin binding to the 
receptors [26]. H63D mutations are more frequent than C282Y, with approximately 15% 
of non-Hispanic Whites being carriers of the mutation in the US, and 3% having two 
copies [23]. The penetrance of H63D is low, and the variant needs to be coupled with the 
C282Y variant in order to have an effect on iron levels. However, C282Y and H63D can 
never exist on the same chromosome. 
A third mutation, rs1800730 (S65C), consists of an adenine to thymine 
substitution at position 193, causing the amino acid serine to change to cysteine at 
position 65 [27]. Studies have shown that this variant is associated with a mild form of 
hemochromatosis [28], having a greater effect when found in the presence of other HFE 
variants [29]. S65C is less common than C282Y and H63D, found in less than 5% of the 
non-Hispanic White population [28]. 
The SNP rs807212 was identified as tagging for the most common HFE region 
haplotype [30]. This intergenic SNP appears to tag for the wild-type alleles for all HFE 
variants, meaning the haplotype lacked all disease-associated variants [30]. There was a 
strong gender effect noticed with this SNP. Males had strong protective association 
against childhood leukemia, which made biological sense as male carriers of the variant 
rs807212 were therefore absent of the C282Y mutation, which had previously been 
associated with childhood leukemia risk [30-32]. 
 The transition substitution in intron 1 creates the HFE SNP rs9366637. This SNP 
has been identified as a tagging SNP as well, but has not been studied extensively. It has 
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not yet been implicated in iron regulation, however, the haplotype tagged by rs9366637 
lacks C282Y and H63D. The minor allele frequency for this SNP varies greatly 
depending on the race/ethnicity of the population, with the CEU (Western European 
ancestry) T-allele frequency being 0.06 and the HCB (Han Chinese in Beijing, China) 
having a MAF of 0.49. The variant (T) allele has been shown to be a marker of increased 
birth weight in European childhood ALL patients [18]. In a case-control study in a Han 
Chinese population, the C allele was found to be a significant risk marker for coronary 
heart disease (CHD) [33]. In a meta-analyses study looking at HFE gene variants and 
CHD in Han Chinese, only an association with rs1799945 variant allele increased risk for 
CHD, and the association with rs9366637 did not reach overall statistical significance 
[34]. The SNP was also found to be a marker for height in a GWAS [35]. 
Disease associations with HFE mutations 
Hereditary hemochromatosis 
Hemochromatosis describes any disorder caused by iron excess and tissue injury 
[25]. Hereditary hemochromatosis (HH) is the most commonly inherited form of iron 
overload. This autosomal recessive disorder may lead to severe organ dysfunction over 
time because of high iron absorption [25]. It is estimated that 90% of those with HH who 
are of northern European descent are homozygous for the C282Y mutation [36]. It is very 
common in that particular population, affecting 1 in every 200-300 individuals [37]. The 
condition is expressed more severely in males rather than females, as women are able to 
reduce their iron levels through the loss of blood during menstruation and childbirth [38].  
Homozygosity for the C282Y variant or heterozygosity of C282Y and H63D on 
separate chromosomes are the two primary genetic combinations that cause HH [37]. 
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When the C282Y mutations are present, the mutated HFE protein is no longer able to 
interact with transferrin receptors and hepcidin on at the cell surface [37]. Low hepcidin 
production is a result of the mutation, causing the cells to think iron levels are low and 
absorption is necessary. The excessive storage occurs primary in the liver, heart, joints, 
pancreas, skin, and testes [39]. Homozygosity of H63D on its own will not cause HH, but 
with a C282Y mutation may [40]. Determining the penetrance of the disorder is difficult 
to assess [41], as many patients do not show any signs or symptoms, particularly those 
who are heterozygotes [37]. Even with those that do show symptoms, they take a long 
time to develop, and clinical indicators are not apparent until at least middle age [31].  
The horizontal bar chart depicted in Figure I represents the probability of developing HH 
based on HFE genotype. The highest risk is among C282Y homozygotes, with risk 
decreasing gradually for C282Y/H63D heterozygotes, H63D homozygotes, and C282Y 
heterozygotes. Homozygosity for H63D has the same risk as individuals who are not 
carriers of any HFE variants. 
Once symptoms of iron excess develop, they can range from mild iron elevation 
to severe heart and liver disease [37]. Early symptoms include weight loss, lethargy, and 
stomach pain [39]. The liver is the first organ to typically show signs of HH, with 
hepatomegaly developing frequently [38]. Approximately 10-15% of patients with 
hepatocellular carcinoma have HH [38,42]. Other disorders that may stem from HH 
include diabetes, cardiomyopathy, and hyperpigmentation [38]. 
Hereditary hemochromatosis can be diagnosed by checking transferrin-iron 
saturation (TS) and serum ferritin concentrations. Serum transferrin-iron saturation 
greater than 50% in women and 60% in men is common in individuals with HH [38]. It is 
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not feasible to do prenatal testing for HH, since the disorder is treatable. The only way to 
treat HH is by removing iron from the body. The easiest way to do this is through 
phlebotomy. Individuals with HH should also monitor their iron intake, from both 
mineral supplements and with food choices [5].  
Disease associations 
 Iron excess has been implicated in many different cancers and diseases, described 
in Table II. Studies have shown that iron can affect carcinogenesis by either suppressing 
the hosts’ defense cells, acting as a nutrient for growing tumor cells, or by increasing 
oxidative stress with an increase in free radicals [17].  Free radical generation leads to 
inflammation and mutagenesis within the body [43]. Hereditary hemochromatosis is a 
well-established model of iron-induced carcinogenesis [10].  
Many HH patients develop cirrhosis of the liver, and are at an increased risk for 
liver cancer. Primary hepatocellular carcinoma, in particular, is 200 times more common 
in these patients [42]. The liver is the major site of iron storage, therefore liver disorders 
are not surprising in HH patients. Increased risk for liver cancer has been seen not only in 
HH patients, but also in non-HH individuals with iron overload [44,45]. HH patients are 
also at an increased risk for diabetes [42]. The mechanism is not clearly understood, but it 
is hypothesized that iron accumulation damages pancreatic beta cells and insulin 
resistance [46]. Heart conditions such as cardiomyopathy and arrhythmias have been 
observed in in high numbers of HH patients as well [38]. Studies have shown that 
reducing iron stores through blood donation reduces the risk for heart disease [43]. 
Whether or not the C282Y mutation is a risk factor for developing heart disease is still 
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debated. Factors including smoking and hypertension status in women with heart disease 
may confound the association [47]. 
 Many studies have explored the association between neurodegenerative disorders 
association and iron accumulation in the brain [48].  Iron accumulation is consistently 
observed in Alzheimer disease (AD) and its involvement in neuritic plaques has been 
well documented [49]. AD is enhanced by oxidative stress, and excess free iron would 
lead to oxidative stress through generation of free radicals in the neurons. Both C282Y 
and H63D have been associated with an increased risk for Alzheimer [26,50-52]. 
HFE variants and childhood leukemia risk 
 
Previous studies have examined the risk association between HFE mutations and 
childhood acute lymphoblastic leukemia (ALL) risk [18,31,32,53,54]. The C282Y 
mutation was reported to be a risk factor for male children in a case-control study of 
Welsh and Scottish populations [53]. The minor allele frequencies for C282Y in males 
was 23.4% in cases and 12.3% in controls for the Wales population, and 34.7% in cases 
compared to 15.1% in controls in the Scotland group [53]. These populations are quite 
homogenous; therefore the generalization of the findings is unknown. H63D did not show 
any association with childhood ALL risk.  
A Finnish study [55] is the only other published study that looked at HFE variants 
in childhood leukemia. The study population only included 32 childhood ALL patients, 
of which 14 were male, and did not find any significant results. Other hematologic 
malignancies studies on acute myeloid leukemia [56] and Hodgkin disease [32] have 
found no risk associations with HFE variants, and a myelodysplastic syndrome study [57]  
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revealed a positive association, which was not been replicated in a different population 
sample [58]. 
Mechanism 
 It is speculated that most cancer risk associated with increased iron levels is due 
to iron accumulation over years, resulting in chronic oxidative stress. The association 
with childhood leukemia cannot therefore be explained by this same reasoning. 
Chitambar et al. have suggested that increased intracellular iron levels in lymphoid cells 
during development may explain the risk [59]. Cell studies have shown that B-lymphoid 
cell lines that are homozygous for the C282Y variant demonstrate greater iron uptake and 
increased cell sensitivity to oxidative stress [59]. The increase in oxidative stress due to 
the high iron levels may increase radiation sensitivity, which has been shown to increase 
cancer susceptibility [60,61].  Lymphocytes can be radiation sensitized by iron, and 
Stevens et al. have identified C282Y heterozygotes as risk factors for radiation sensitivity 
[62,63]. Growing fetuses are sensitive to environmental insults, and those who are 
carriers of the C282Y variant may be exposed to higher intracellular levels of iron, 
especially if their mother is a carrier [31]. This hypothesis, of course, must be carried out 
in functional studies to determine its validity. 
 Another idea is that the HFE gene may play a role with immune function [53]. 
Mutations in HFE causing iron overload may interfere with the immune function of 
lymphoid cells, and be an underlying reason for the association with childhood leukemia 
risk. The role of HFE with the histone proteins may also be important [30]. The HFE 
gene is flanked by histone coding genes on both sides, and histones are known to be 
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important in genome biology and potentially with tumor suppression [30]. There may be 
similarities between the two or interactions between the genes that are unknown.  
 
Conclusion 
 With well-known biology of its effects, iron excess is likely to have more impact 
on cancer and neurodegenerative diseases in the Western world. Iron supplementation is 
currently unregulated and non-personalized, with every male and female given the same 
suggested amount to intake. Educating the public on lifestyle modifications for those with 
iron overload such as controlled iron supplementation and avoidance from the 
unnecessary consumption of iron-rich food, could reduce ill side effects from the 
disorder. After decades of serological work trying to determine the effects of iron 
accumulation in the body, genetic epidemiology has made more of an impact in a shorter 
period of time. 
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Table I. GWAS findings for HFE polymorphisms* 
PMID** Trait SNP 
19820699 
Iron status biomarkers 
rs1800562 
19084217 
21483845 
23446634 Red blood cell traits 20927387 
20858683 Glycated hemoglobin levels 
19820697 Hematological parameters 
21785125 Hepcidin levels 
21943158 Cardiovascular disease risk factors 
19862010 
Hematocrit 
Hemoglobin 
Mean corpuscular volume 
23263863 Hematology traits Mean corpuscular hemoglobin 
20686565 Cholesterol, total LDL cholesterol 
21909115 
Diastolic blood pressure 
rs1799945 Hypertension Systolic blood pressure 
21208937 Iron levels 
19820698 Hemoglobin 
rs198846 20139978 Mean corpuscular volume 
21909110 Blood pressure 
19853236 Hematology traits rs1408272 21149283 Iron status biomarkers 
21149283 Iron status biomarkers rs17342717 
 
*Hindorff LA, MacArthur J (European Bioinformatics Institute), Morales J (European Bioinformatics 
Institute), Junkins HA, Hall PN, Klemm AK, and Manolio TA. A Catalog of Published Genome-Wide 
Association Studies. Available at: www.genome.gov/gwastudies.  Accessed September 10, 2013. 
 
**PubMed identifier number 
 
 
 
31 
 
Table II. Characteristics of most studied SNPs in the HFE gene 
 
 Minor allele and frequency** 
SNP Nucleotide position* 
Polymorphism type and 
location Sequence CEU YRI JPT HCB 
rs1800562 26093141 
Coding; nonsynonymous; 
substitution of cysteine (C) 
by tyrosine (Y) at amino 
acid position 282 (C282Y) 
ATATACGT(A):(G)CCAGGTGG (A) 0.053 NA NA NA 
rs1799945 26091179 
Coding; nonsynonymous; 
substitution of histidine 
(H) by aspartate (D) at 
amino acid position 63 
(H63D) 
TCTATGAT(C):(G)ATGAGAGT (G) 0.179 (G) 0.00 (G) 0.042 (G) 0.125 
rs1800730 26091185 Transversion substitution (S65C) ATCATGAG(A):(T)GTCGCCGT (T) 0.033 NA NA NA 
rs807212 26065621 Transition substitution, intergenic TTTTACCC(A):(G)GGAGTGGA (A) 0.358 (A) 0.042 (A) 0.091 (A) 0.089 
rs9366637 26089098 Intronic, transition substitution (IVS1) TTTGCATT(C):(T)TAGTGGGA (T) 0.066  (T) 0.075  C 0.385  (T) 0.493  
rs2794719 26088890 Intron, transversion substitution, intragenic CAAAGCCC(C):(A)GTGTACCA (C) 0.397 (C) 0.155 (A) 0.302 (A) 0.256 
rs2858996 26094026 Transversion substitution, intron/intragenic GAGTTTGC(T):(G)TAGCTATC (T) 0.208  (T) 0.089  (T) 0.066 (T) 0.179  
rs2071303 26091336 Transition substitution, intron, intragenic  CTCTCCAC(A):(G)TACCCTTG (G) 0.341 (G) 0.401 (A) 0.221 (A) 0.367 
rs1800708 26093303 Transition substitution, intron, intragenic GGGTGGGC(C):(T)GAGGGTGG (C) 0.080 (C) 0.088 (T) 0.319  (T) 0.456  
rs1572982 26094367 Intron, transition substitution, intragenic GCAAGATG(A):(G)TGCCTAGG (A) 0.456 (G) 0.312  (G) 0.159 (G) 0.296  
 
*Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide position (http://www.ncbi.nlm.nih.gov/SNP/) 
**Population descriptors: 
CEU (C): Utah residents with Northern and Western European ancestry from the CEPH collection 
YRI (Y): Yoruban in Ibadan, Nigeria 
JPT (J): Japanese in Tokyo, Japan 
HCB (H): Han Chinese in Beijing, China
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Figure I. Likelihood of developing adverse health effects from hereditary 
hemochromatosis based on HFE genotype 
 
Adapted from: Khoury MJ, Burke W, Thomas EJ, editors. Genetics and Public Health in the 21st Cen  
Using Genetic Information to Improve Health and Prevent Disease. New York: Oxford Press; 2000. 
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Table III. Conditions showing increased risk associations with HFE variants 
Condition PMID* 
Alzheimer disease 12707938, 15060098, 11445256, 10861683, 20029940, 17119292 
Amyotrophic lateral sclerosis 17828789 
Arthritis 12401309, 17284543, 16468045, 16583477, 16638105 
Breast cancer 10383894, 14973098, 20099304, 16216474, 16503999, 23681799  
Cardiovascular disease 12401309, 21696736, 20640879, 17389307 
Cervical cancer 16414021 
Childhood acute lymphoblastic leukemia 19806355, 10627122 
Colon Cancer 
10383894, 12529348, 20099304, 
19291797, 15941956, 23553028, 
23281741 
Diabetes 8613000, 9654270, 9726605, 9885759, 22908207 
Gastric cancer 23389292 
Glioma 11591868, 19386095 
Hepatic veno-occlusive disease 15834437 
Liver cancer 
10845668, 10989544, 11500061, 
12003382, 15929796, 15017669, 
18164971, 23281741, 10918159, 
12591066, 1312985, 4058506, 8613000 
Neurodegenerative diseases 12401309, 23813494, 22526559, 21349849, 21346098 
Ovarian cancer 20669231, 21879820 
Prostate cancer 16003728 
 
*PubMed identifier number 
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CHAPTER IV 
 
GENETIC MARKERS IN A MULTI-ETHNIC SAMPLE FOR CHILDHOOD 
ACUTE LYMPHOBLASTIC LEUKEMIA RISK 
 
Abstract 
Genome-wide association studies (GWAS) have identified multiple risk loci for 
childhood acute lymphoblastic leukemia (ALL), but mostly in European/White 
populations, even though Hispanics have a greater risk compared to the European/White 
population. We re-examined selected SNPs of known associations with childhood ALL 
and known HLA region lymphoma risk markers in a multi-ethnic population sample from 
Houston, Texas consisting of 161 incident childhood ALL cases and 231 controls. 
Significant associations were found in two ARID5B variants (rs7089424, ORallele=1.69, 
P<0.001; and rs10821936, ORallele=1.48, P=0.005), as previously shown in GWAS. 
Marker rs2395185, which is a protective marker for lymphoma, replicated the previously 
found strong risk association with childhood ALL in non-Hispanic White males 
(ORallele=2.79, P= 0.02), but no association was noted in Hispanics. Another HLA region 
marker rs2647012 showed a statistically significant risk association among Hispanics, but 
not in non-Hispanics (Pinteraction = 0.003 for ethnicity). A strong statistically significant 
protective association was found with rs1048456, a risk marker in follicular lymphoma 
(ORrec=0.19, P=0.009). Our study validated this new case-control sample by confirming 
some of the previously discovered genetic markers associated to childhood ALL, and 
yielded new associations with known lymphoma markers. The association of lymphoma 
markers were in opposite direction in childhood ALL. Despite positive results, our study 
did not provide any clues to why Hispanics have a higher susceptibility to childhood 
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leukemia, suggesting that environmental factors may have a stronger contribution to this 
differential. 
Introduction 
 Over a third of cancers in children are leukemias [1], with acute lymphoblastic 
leukemia (ALL) being the most common [2-4]. Approximately 3.8 individuals (less than 
14 years of age) per 1,000,000 are diagnosed with childhood ALL per year in the United 
States [5].  The racial disparity in the incidence of childhood ALL has been well 
established [6,7]. In the United States, incidence of ALL is greatest in Hispanic children, 
followed by non-Hispanic Whites, Asians, and then Blacks [7-9]. 
Research continually tries to determine the etiology of childhood leukemias. 
While there are a few known risk factors associated with childhood ALL [10-15], more 
than 90% are of unknown etiology [11]. Increased birth weight is an established risk 
factor shown to increase risk of childhood ALL [16-33]. Environmental factors are also 
involved, and may work in conjunction with genetic factors to cause many cancers [10]. 
Genome-wide association studies (GWAS) [34-37] have identified multiple risk 
loci showing significant associations with childhood ALL. Most significantly, variants 
located within the ARID5B, IKZF1, and CEBPE genes have robust risk associations. 
Most of these studies, however, have only evaluated risk among those of European 
ancestry. Two multiethnic studies conducted by Xu et al. looked at various risk loci in 
both African American and Hispanic American populations [8,37], discovering that some 
markers are universal across races/ethnicities, while others are race/ethnic-specific.  
We re-examined five previously discovered single nucleotide polymorphisms 
(SNPs) of known associations to leukemia (rs7089424, rs10821936, rs10994982, 
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rs4132601, and rs2239633), along with three HLA region susceptibility markers for 
lymphomas, since lymphoma and ALL both stem from lymphoid cells. These included 
rs2395185, a marker of HLA DRB4 lineage [38] which has previously shown risk 
associations with major leukemias including childhood ALL and other diseases [39-49]; 
rs10484561, which has been shown to be a strong risk marker in follicular lymphoma 
(FL) [50]; and rs2647012, which is a protective marker for FL [51]. These SNPs were 
examined in a multi-ethnic sample (non-Hispanic Whites, Hispanic Whites, and Blacks) 
from Houston, Texas to assess their association with ALL. We hypothesized that the 
variation in ethnic/racial susceptibility to childhood ALL has a genetic basis. 
Subjects and Methods 
Study population 
Institutional Review Board (IRB) approval was received at both the Baylor 
College of Medicine (BCM) and Florida International University prior to the start of the 
study. The case-control study comprised of 161 incident childhood ALL cases and 231 
healthy age-matched controls contemporaneously recruited at the Texas Children’s 
Cancer Center, at BCM in Houston, TX from 2007 to 2012. The children were less than 
18 years of age at diagnosis, and exclusion criteria for both cases and controls were 
refusal to participate in the study and the diagnosis of any other disease or cancer. 
Subjects or their parents provided informed consent for provision of epidemiological data 
with a questionnaire and a biological sample. The DNA samples were extracted from 
saliva or peripheral blood samples at BCM. Race/ethnicity was determined by the 
responses provided on the questionnaire. Parents were requested to state the race (White, 
Black/African American, Asian, American Indian/Alaska Native, or Native 
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Hawaiian/Other Pacific Islander) and ethnicity (Hispanic/Latino or non-Hispanic/Latino) 
of the child. The questionnaire also collected the race/ethnicity of the parents, which was 
used to verify the response. Information on clinical subtype of ALL was collected from 
medical records.  
Genotyping 
The main features for the SNPs genotyped are shown in Table I. Pre-developed 
TaqMan® SNP Genotyping Assays (LifeTech, Foster City, CA) were used for all of the 
SNPs we examined. Genotyping was achieved using the Bio-Rad CFX96 real-time PCR 
machine (Hercules, CA). The TaqMan assays consist of singleplex reactions carried out 
in ninety-six well plates. Each plate contained two no template controls (NTCs), a 
positive control, and random replicate samples. Bio-Rad SsoFast™ Probes Supermix, a 
2x reaction buffer which contains the necessary components for running the PCR; Sso7d-
fusion polymerase, dNTPs, MgCI2, and stabilizers, was used with the TaqMan Assay.  
PCR amplifications were performed using the manufacturer’s suggestion of 20 µL total 
volume and with the following PCR thermal cycling conditions: enzyme activation at 
95oC for two minutes, and 49 cycles of denaturation at 95oC for 5 seconds followed by 
annealing and extension at 61oC for 5 seconds. Bio-Rad CFX Manager software (version 
3.0) was used for data acquisition and genotype assignment. 
Statistical analysis 
 Statistical analyses were performed using Stata v.11 (StataCorp, College Station, 
TX).  Pearson’s Χ2, Student's t-test (for means) or median test (for medians) were used to 
compare characteristics between the cases and controls. Logistic regression methods were 
used to calculate crude and adjusted odds ratios (OR) and 95% confidence intervals (CIs). 
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All statistical tests were two-tailed, and the threshold for statistical significance was set at 
P≤0.05. The ORs, with 95% CIs, were used as a measure of effect size. Genotype counts 
were tested for Hardy–Weinberg equilibrium (HWE) in controls for each SNP. By 
default, we used the additive genetic model to assess associations by Cochrane-Armitage 
trend test. Due to its previous association being in the recessive model, rs2395185 was 
analyzed also for the recessive model association. Ethnic- and gender-specific 
associations were calculated through stratified analyses. None of the SNPs were located 
in coding regions, therefore we used RegulomeDB (Stanford University, Palo Alto, CA) 
to calculate a score for regulatory function. To adjust for heterogeneity in our sample, 
especially in Hispanics, we used two ancestry-informative markers, AIMs, to control for 
confounding caused by population stratification and to avoid spurious associations [52]. 
The two AIMs we used, rs285 and rs2891, have been previously used in Hispanic 
populations to account for the differences in genetic ancestry [53,54]. The risk 
associations were adjusted by each of the AIMS.  
Results 
 All cases and controls were genotyped for the eight candidate SNPs and two 
ancestry-informative markers (AIMs). Genotype call rates were greater than 95% for both 
cases and controls.  Table II shows characteristics of the case-control sample. The case 
samples included 86 males (53%) and 75 females (47%). Out of these cases, 66 identified 
themselves as non-Hispanic White, 72 as Hispanic White, 17 as Black, and 6 as “other.” 
The group labeled “other” included those identifying themselves as Asian, Native 
American, or other. The healthy controls included 130 males (56%) and 101 females 
(44%), who had visited the pediatric clinic at BCM for a non-disease related reason. 
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Forty-nine were classified as non-Hispanic White, 98 as Hispanic White, and 78 as 
Black. The distribution of ethnic background was different between cases and controls 
mainly due to the infrequency of childhood ALL. Because of this difference, results were 
adjusted for ethnic background or stratified analyses were performed when necessary. 
There was no significant difference in the means between the case/control groups in 
regards to birth weight. Birth length and gestational age did not differ between cases and 
controls, except in specific subgroups. There was a significant difference in gestational 
age between cases and controls, only in the Hispanic female subgroup. The difference in 
birth length means was significant, but only in the non-Hispanic White subgroup. Eighty-
eight percent of the cases were diagnosed with early precursor B (early pre-B) ALL 
subtype, and associations did not change in effect size depending on the molecular 
subtype. There were no significant genotype associations found within the Black 
subpopulation, possibly due to the small number of cases in the population sample.  
GWAS risk markers 
Results including genotype frequencies and odds ratios are described in Tables 
III-V. Analyses yielded significant associations with some of the genetic markers similar 
to previous reports. In total, three ARID5B SNPs were examined for associations. Two of 
the ARID5B SNPs, rs7089424 and rs10821936, showed expected risk associations, while 
rs10994982 did not show an association (Table III). The SNP rs7089424 had an overall 
odds ratio per allele (ORallele) of 1.69 (P>0.001). The association showed a somewhat 
stronger risk in the non-Hispanic subgroup (ORallele=2.11, P=0.01), compared with 
Hispanics (ORallele=1.61, P=0.02). Similarly, rs10821936 had an overall ORallele=1.48 
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(P=0.05). Adjustments of the analyses for race/ethnicity did not change the observed 
results. Adjustment for AIMs did not appreciably alter the results either. 
There were no significant associations found for IKZF1 rs4132601 or for CEBPE 
rs2239633. Hardy-Weinberg equilibrium was violated in controls for rs4132601, which 
could lead to spurious results, and was therefore excluded. 
HLA region lymphoma risk markers 
 The SNP located in the HLA-DR region, rs2395185, showed a weak, non-
significant risk overall (Table IV). This SNP is an exclusive marker for the HLA-DRB4 
(DR53) lineage [38]. Since this lineage was shown to be a risk marker for childhood 
ALL, but only in males [46], we examined rs2395185 association in males. The non-
Hispanic White male group had an ORallele of 2.79 (P=0.016). Figure I depicts the 
childhood ALL risk in rs2395185 subgroup analysis, focusing on males and non-Hispanic 
White males, specifically. The OR reached 6.21 (95% CI=0.70-54.96) for homoyzgosity 
for the variant allele, which corresponds to the original association [46]. The known 
protective marker for follicular lymphoma, rs2647012, showed a statistically significant 
association in Hispanics ORallele =2.21 (P=0.007), but not in non-Hispanics (Pinteraction = 
0.003 for ethnicity), as shown in Figure II. The significance remained after adjusting for 
both rs23951885 and rs10484561. The variant rs10484561 was shown to be a strong 
protective marker in this study, opposite of what was found in follicular lymphoma [50]. 
Using the recessive model, the variant allele showed a strong association, ORrec=0.19 
(P=0.009). The two AIMs used, rs285 and rs2891, did not show any association as 
expected (Table V). 
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Discussion 
 Despite being well established, the racial disparity in the incidence of childhood 
ALL is not always addressed in genetic association studies. Most GWAS, until recently, 
have identified risk loci using only European-origin populations. Variant polymorphisms 
located within the ARID5B, IKZF1, and CEBPE genes have reported strong risk 
associations in multiple GWAS [34-37,55-57]. Our study provides some confirmation of 
previously discovered genetic markers associated with childhood ALL, which also 
validated our case-control set for further exploration. 
Of the three ARID5B SNPs, rs7089424 and rs10821936 showed significant risk 
associations, and rs10994982 did not show any associations. The ARID5B gene is 
involved in transcriptional regulation with embryonic development [55]. Overexpression 
of the gene in particular acute leukemias have led some to speculate that variations within 
the gene may affect B-lineage development, and increase susceptibility to B-lineage 
leukemia [35]. The marker rs7089424 was associated with a stronger risk of leukemia in 
the non-Hispanic subgroup compared with Hispanics, replicating recent findings from 
case-control studies using Hispanic populations [8,37]. 
In the recent multi-ethnic GWAS by Xu et al., rs10821936 was found to be a 
significant risk marker across all ethnicities. Xu et al. noted that the risk allele 
frequencies for rs10821936 increased in order by race incident rates: Black/African 
Americans, non-Hispanic/European American, and Hispanic Americans [37].  Our results 
showed a similar trend with an increasing risk allele frequency (RAF) in cases of Blacks, 
non-Hispanic Whites and Hispanics. The multi-ethnic GWAS reported that rs10821936 
was highly correlated with Native American genetic ancestry [37], substantiating their 
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previous observations that Native American ancestry correlates with higher risk of 
relapse in Hispanics, and leading to speculation that this may be a factor with the 
increased risk for Hispanic children who have a high proportion of Native American 
ancestry [58]. 
The SNP rs4132601, located in the Ikaros family zinc finger 1 (IKZF1) gene, is 
associated with increased risk of childhood ALL in multiple studies [34,36,56,57,59]. 
The Ikaros proteins are known to be involved with lymphocyte development and 
differentiation [34], and deletions are frequent and associated with unfavorable prognosis 
in B-cell precursor ALL [34, 60]. One study found this variant to be a significant risk 
marker amongst non-Hispanic Whites, but not in Hispanics, despite similar allele 
frequencies [57]. Chokkalingam et al. hypothesized that that this marker’s association 
may be due to linkage disequilibrium with a functional variant, and because of admixture 
in Hispanic populations the linkage disequilibrium may vary [57]. Our study was unable 
to examine this SNP, due to Hardy-Weinberg disequilibrium found in controls, even after 
stratification for race/ethnicity.  
The present study confirmed some, but not all previous findings of GWAS. With 
the ARID5B risk SNPs, there was heterogeneity even between the first two GWAS 
reports [34,35]. The modest sample size we had also reduced the statistical power of our 
study. Nevertheless, confirmed results validated the present case-control sample for 
further genetic association studies. 
The relevance of lymphoma-associated polymorphisms in childhood ALL was 
assessed by genotyping rs2395185, rs10484561, and rs2647012. The SNP near the HLA-
DRA gene, rs2395185, is a marker for the HLA-DRB4 (DR53) lineage [38].  The HLA-
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DRB4 lineage or its marker SNP have been previously shown as a risk marker in lung 
cancer [39], asthma [40], rheumatoid arthritis [49], type I diabetes [48], adult acute 
myeloblastic leukemia [61], chronic myeloid leukemia [62], chronic lymphoid leukemia 
[63-65] and in childhood ALL (males only) [46,66,67], and as a protective marker for 
non-Hodgkin lymphoma [41], and ulcerative colitis [42-44,47]. The DRB4/DR53 lineage 
has been shown previously to have a risk association with childhood ALL, with male 
specificity, within a European sample via HLA typing [46]. The first GWAS association 
of rs2395185 was with ulcerative colitis [42,47]. The variant allele, T, was later found to 
be a protective marker in a GWAS examining risk factors for classical Hodgkin 
lymphoma [41], and most recently a risk marker factor in Asian females for lung cancer 
[39]. Our results replicated the strong male specificity of the risk for childhood ALL, 
specifically in non-Hispanic White males, with no association in Hispanics. The DRB4 
lineage has unique features, such as lower expression levels of HLA-DR molecules, poor 
interaction with CD4, disrupted intracellular transport, and possibly contains extra 
amount of DNA in the DR/DQ region which may contribute to this risk association in 
childhood ALL [45]. One important finding of the present study is that the risk modifiers 
of lymphoma showed opposite associations in childhood ALL. 
 The variant rs2647012, a marker for DRB3/DRB5 lineages and a protective 
marker for lymphoma, showed a statistically significant risk association among 
Hispanics, but not in non-Hispanics (Pinteraction = 0.003 for ethnicity). Our study appears to 
be the first looking at a Hispanic population with this SNP, and further studies are 
warranted to determine if this inverse relationship of risk exists in non-Hispanic and 
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Hispanic Whites. Variant rs10484561 showed signs of being a protective marker for 
childhood ALL, opposite to the follicular lymphoma findings [50].  
It is now customary that the additive model is used to assess statistical 
associations of SNPs. While the additive model has sufficient power to detect 
associations in most situations, there are certain scenarios that it may not show statistical 
significance when in fact, there is an association. An association conforming to the 
strictly recessive model when allele frequency is low is one example [68-70]. For this 
reason, and also because the original rs2395185 association was a recessive model 
association, we also assessed this genetic model in HLA region associations. This 
approach consistently yielded larger effect sizes for HLA region SNPs, especially for 
rs2395185 as in previous studies. We are in favor of routine use of the recessive model 
analysis in exploration of associations in the HLA region. 
There are limitations of our study. With childhood ALL being a rare disease, the 
sample size for our study was small, resulting in limited statistical power. The issue of 
self-reported ethnicity may also be of concern. This method is common with population-
based association studies, and residual confounding is often suspected. Even though it has 
been described that self-reported ethnicity may be reliable [71], the heterogeneity within 
the Hispanic population is still a concern. A recent study conducted in a Spanish 
population was unable to replicate original risk associations found in Hispanic 
Americans, demonstrating the large heterogeneity in this high risk group [37,72].  
To adjust for heterogeneity in our sample, especially in Hispanics, we used two 
ancestry-informative markers, AIMs, to control for confounding caused by population 
stratification and to avoid spurious associations [52]. The AIMs have widely different 
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allele frequencies in major human continental groups. The two AIMs we used, rs285 and 
rs2891, have been previously used in Hispanic populations to account for the differences 
in genetic ancestry [53,54]. Adjusting the risk associations by AIMs did not alter the 
results.  
 Our study did have a well-defined phenotype, with molecular ALL types 
determined. The use of a multi-ethnic sample population was a strength, especially for 
the ethnic disparity that persists with childhood ALL. Another strength is the use of 
multiple genetic models, where appropriate, to determine associations that may remain 
undetectable by the exclusive use of the additive model association. The replication of 
known leukemia markers validated our sample set for further studies. This pilot study is 
part of an ongoing effort at BCM. Recruitment for the second phase is continuing 
together with clinical follow-up.  
In summary, we validated a new multi-ethnic case-control set and also examined 
some new markers with their association with childhood ALL. The examination of 
lymphoma risk markers yielded associations in opposite directions for childhood ALL, 
but also confirmed a previously identified childhood ALL risk marker. Two HLA region 
associations were ethnicity-specific. Still, our study did not provide clues as to why 
Hispanics have a higher susceptibility to childhood ALL, suggesting that environmental 
factors may play a stronger role in this differential. Studies with information on 
environmental exposures may help explain how gene-environment interactions contribute 
to childhood ALL susceptibility and its variation among different populations. 
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Table I.  Main features of SNPs analyzed 
 
Gene SNP Chromosome nucleotide position* Inclusion criteria PMID
** Minor allele and frequency† Location 
RegulomeDB 
score†† 
ARID5B rs7089424 chr10: 63752159 GWAS identified risk loci for childhood ALL 
19684604, 22660188, 
20042726 (G) 0.314 Intronic 3a 
ARID5B rs10821936 chr10: 63723577 GWAS identified risk loci for childhood ALL 
19684603, 20054350, 
22660188, 23512250, 
22291082 
(C) 0.318 Intronic 5 
ARID5B rs10994982 chr10: 63710104 GWAS identified risk loci for childhood ALL 19684603, 22660188 (A) 0.457 Intronic NA 
IKZF1 rs4132601 chr7: 50470604 GWAS identified risk loci for childhood ALL 
19684604, 22660188, 
20054350 (G) 0.306 3'-UTR 5 
CEBPE rs2239633 chr14: 23589057 GWAS identified risk loci for childhood ALL 19684604, 22660188 (A) 0.466 
5'-
upstream 4 
HLA-DR 
region rs2395185 chr6: 32433167 
HLA-DRB4/DR53 
lineage; ALL risk 
marker (in European 
males); Hodgkin 
lymphoma risk marker 
10397736, 12008082, 
22286212, 7909466  (T) 0.423 Intronic 6 
HLA-DQB1 
region rs2647012 chr6: 32664458 
HLA-DRB3/DRB5 
lineage, protective 
marker for non-Hodgkin 
(follicular) lymphoma 
21533074, 22911334, 
23455380 (T) 0.381 Intergenic 6 
HLA-DQA1 
region rs10484561 chr6: 32665420 
HLA-DR1/DR10 
lineage, risk marker in 
follicular lymphoma 
20639881, 21533074, 
23025665 (G) 0.084 Intergenic 6 
 
*Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide position (http://www.ncbi.nlm.nih.gov/SNP/) 
**PubMed identifier number 
†Minor allele frequencies are from a reference Caucasian population (U.S. residents of northern and western European ancestry) genotyped in HapMap 
project 
††RegulomeDB scores range from 1 (most functional) to 5 (least functional) (6=other). Not all SNPs have a RegulomeDB score 
(http://regulome.stanford.edu/) 
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Table II. Characteristics of cases and controls 
 
  
Cases  
n=161 
Controls 
n=231 
P value 
Ethnic background  
  Non-Hispanic White 
  Hispanic White 
  Black 
  Other* 
 
66 
72 
17 
6 
 
49 
98 
78 
6 
<0.001 
Gender 
  Male 
  Female 
  Ratio 
 
86 
75 
1.15 
 
130 
101 
1.29 
0.58 
Birth weight (grams) 
  Mean (SD) 
  Median (IQR) 
 
3349.3 (584) 
3400 (760) 
 
3263.3 (684) 
3311.5 (850) 
 
0.23 
0.48 
Gestational age (weeks) (SD) 38.8 (2.2) 38.2 (2.8) 0.04 
Birth length (cm) (SD) 51.4 (3.4) 50.1 (5.05) 0.024 
 
*Other includes Asian, Native American, or other 
55 
 
Table III. SNP associations previously shown as ALL risk markers in GWAS (overall*) 
 
  Case Subjects Control Subjects Minor Allele Frequency   
Gene SNP Minor Allele A/A A/B B/B A/A A/B B/B Case Control ORallele
**(95% CI) P value 
ARID5B rs7089424 G 37 80 43 113 68 46 0.52 0.35 1.69 (1.28-2.24) <0.001 
ARID5B rs10821936 C 39 72 44 104 69 50 0.52 0.38 1.48 (1.12-1.95) 0.005 
ARID5B rs10994982 A 55 78 25 90 78 43 0.41 0.39 1.00 (0.75-1.34) 0.992 
 IKZF1 rs4132601 G 76 68 16 141 56 29 0.31 0.25 1.19 (0.88-1.60) 0.269† 
CEBPE rs2239633 A 68 68 23 118 74 36 0.36 0.32 1.02 (0.76-1.36) 0.881 
 
*ORs adjusted for self-reported ethnicity and race 
**OR per allele (ORallele) for the additive model 
†Hardy-Weinberg disequilibrium in controls (overall and after stratification) for race/ethnicity 
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Table IV. Association of HLA region lymphoma susceptibility markers (overall*) 
 
  Case Subjects Control Subjects Minor allele frequency 
 
SNP Gene Minor allele A/A A/B B/B A/A A/B B/B Case Control 
ORallele** 
(95% CI) 
P value 
ORrec†  
(95% CI) 
P value 
rs2395185 HLA-DR region T 69 68 22 120 72 25 0.35 0.28 
1.27 
(0.94-1.71) 
0.127 
 1.1  
(0.65-2.26)†† 
0.553 
rs2647012 HLA-DQB1 region A 78 64 16 116 47 30 0.3 0.28 
1.09  
(0.80-1.47) 
0.595 
0.57  
(0.30-1.12) 
0.103 
rs10484561 HLA-DQA1 region G 128 23 3 149 21 18 0.09 0.15 
0.70  
(0.46-1.06) 
0.094 
0.19  
(0.05-0.66) 
0.009 
 
*ORs adjusted for self-reported ethnicity and race           
**OR per allele (ORallele) for the additive model;  
†OR recessive (ORrec) for the variant homozygous genotype  
††ORallele=1.88 (P=0.003) in males; ORallele=2.79 (P=0.016) in non-Hispanic White males  
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Table V. Ancestry-informative marker SNPs* 
 
  Case Subjects Control Subjects Minor allele frequency   
SNP Gene 
Chromosome 
nucleotide 
position** 
Minor 
allele A/A A/B B/B A/A A/B B/B Case Control ORallele (95% CI) P value 
rs285 LPL chr8: 19815189 C 43 68 48 92 61 53 0.52 0.41   1.26 (0.95-1.65) 0.103 
rs2891 ITGAE chr17: 3705526 C 56 66 37 114 72 42 0.44 0.34   1.14 (0.86-1.52) 0.362 
 
*ORs adjusted for self-reported ethnicity and race 
**Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide position (http://www.ncbi.nlm.nih.gov/SNP/) 
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Figure I: Childhood ALL risk in rs2395185 subgroup analysis 
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Figure II: Childhood ALL risk in rs2647012 subgroup analysis 
Overall NHW Hispanics 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
0 0.5 1 1.5 2 2.5 3 3.5 O
dd
s R
at
io
 a
nd
 9
5%
 C
I 
OR=1.09 
P=0.59 
OR=0.72  
P=0.19 
OR=2.21 
P=0.007
P
interaction 
= 0.003 for ethnicity 
60 
 
CHAPTER V 
EXAMINATION OF HFE ASSOCIATIONS WITH CHILDHOOD LEUKEMIA 
RISK AND EXTENSION TO OTHER IRON REGULATORY GENES 
 
Abstract 
 
Hereditary hemochromatosis (HFE) variants that correlate with body iron levels 
also show associations with cancer risk, including childhood acute lymphoblastic 
leukemia (ALL). Two previous studies reported HFE associations with different gender 
effects, but this association has not been evaluated in a US-based population. Using a 
multi-ethnic sample of cases (n=161) and controls (n=231) from Houston, TX, we 
examined two HFE variants (rs1800562/C282Y and rs1799945/H63D), one transferrin 
receptor gene (TFRC) variant (rs3817672/S142G) and three additional iron-regulatory 
gene (IRG) variants (SLC11A2 rs422982; TMPRSS6 rs855791 and rs733655) for their 
associations with childhood ALL.  Being positive for either of the two HFE variants 
(C282Y or H63D) yielded only a modestly elevated odds ratio (OR) for childhood ALL 
risk in males (1.40, 95% CI = 0.83 to 2.35), which increased to 2.96 (95% CI = 1.29 to 
6.80; P = 0.01) in the presence of a particular TFRC genotype for rs3817672 (Pinteraction= 
0.04). These findings were similar to the results reported in previous childhood ALL 
studies. The TFRC genotype also showed an ethnicity-specific association, with increased 
risk observed in non-Hispanic Whites (OR = 2.54, 95% CI = 1.05 to 6.12; P = 0.04; 
Pinteraction with ethnicity = 0.02). Further support to the hypothesis that elevated iron levels 
contribute to leukemia risk came from the three additional IRG SNPs. They all showed 
individual risk associations with childhood ALL in males (OR = 1.52 to 2.60). A 
polygenic model based on the number of variant alleles in these five IRG SNPs revealed 
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a linear increase in risk among males with the increasing number of variants possessed 
(OR = 2.00 per incremental change, 95% CI = 1.29 to 3.12; P = 0.002). Having three or 
more variants in five IRGs was associated with increased risk (OR = 4.12; P = 0.004) 
compared with having none, while corresponding OR in females was 1.22 (P = 0.71). 
Our results replicated previous HFE risk associations with childhood ALL in a US 
population and also demonstrated novel associations for IRG SNPs, thereby 
strengthening the hypothesis that iron excess mediated by genetic variants contribute to 
childhood ALL risk. 
Introduction 
The hereditary hemochromatosis gene, HFE, has shown multiple associations 
with cancer susceptibility [1-7], including risk childhood acute lymphoblastic leukemia 
(ALL) [8], which has been replicated in one other study [9]. In multiple cancers [1], 
including childhood ALL [9], the association of HFE variants with cancer risk gets 
stronger in interaction with a polymorphism in the transferrin receptor gene (TFRC). 
Since HFE and TFRC proteins biologically interact in iron transfer across membranes 
such as intestinal mucosa and placenta, this interaction supports the notion that the 
involvement of HFE variants in cancer risk modification is mediated via their effect on 
body iron levels [10]. Body iron levels have long been known to be positively correlated 
with cancer risk as several cohort studies have shown [11-14], and iron’s carcinogenic 
effect has been well documented [15]. Thus, HFE associations with cancer have strong 
biological plausibility.   
 Recent genome-wide association studies (GWAS) have identified the HFE variant 
C282Y as a major determinant of body iron levels [10]. The mediation of iron 
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homeostasis by genetic variants extends beyond the HFE gene, with the strongest 
association being TMPRSS6 rs855791 [16]. We reasoned that if HFE associations are due 
to their effect on iron levels, other iron regulatory gene (IRG) polymorphisms should 
show similar associations with childhood ALL risk. We therefore aimed to extend our 
study beyond HFE variants to other IRG polymorphisms. To further test our hypothesis 
that HFE variants modify the risk for childhood ALL via their effects on iron levels, we 
also included the TFRC polymorphism that is known to interact with HFE variants in the 
genotyping scheme to test whether this interaction raises the risk of childhood ALL. The 
other IRG do not interact with TFRC biologically, so we did not predict any other 
interaction. To test our hypothesis, we used a new case-control set, which was first 
validated by replicating known childhood ALL associations.  
Subjects & Methods 
Subjects 
Institutional Review Boards of Baylor College of Medicine and Florida 
International University approved the study protocol. The case-control sample was from 
Houston, TX, consisting of 161 incident cases with childhood ALL diagnosed at Texas 
Children’s Hospital from 2007 to 2012, and 231 age-matched healthy controls 
contemporaneously recruited. The children were less than 18 years of age at diagnosis, 
and exclusion criteria for both cases and controls were refusal to participate in the study 
and the diagnosis of any other disease or cancer. Subjects and their parents were 
approached to obtain informed consent for provision of epidemiological data with a 
questionnaire and a biological sample. The DNA samples were extracted from saliva or 
peripheral blood samples at BCM. The sample was multiethnic to allow us to examine 
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effect modification of childhood ALL risk by race and ethnicity (Table I). Race/ethnicity 
was determined by the responses provided on the questionnaire by the children’s parents. 
Our main interest was the contrast between non-Hispanic Whites (NHW) and Hispanic 
Whites (HW), since childhood ALL is very rare in Blacks, and we had a very small 
number of Blacks in the case group.   
SNP selection 
We included two HFE variants known to influence body iron levels commonly 
known as C282Y (rs1800562) and H63D (rs1799945), as well as the TFRC variant 
S142G (rs3817672), which is known to interact with HFE variants in previously reported 
cancer associations. As other IRG variants, we included the GWAS-identified iron-
related SNP TMPRSS6 rs855791 [16], as well as two additional SNPs we selected also 
from the TMPRSS6 gene (rs733655) and the SLC11A2 gene (rs422982) involved in the 
non-transferrin receptor-related iron transfer across membranes. These two SNPs were 
selected as the promoter region haplotype tagging SNPs for these two genes. The selected 
SNP from TMPRSS6 is 32kb away and not in linkage disequilibrium with the GWAS-
identified marker in the same gene according to the HapMap project European population 
data (r2 = 0.286). Two more SNPs were included as ancestry-informative markers (AIMs) 
to adjust for the racial/ethnic heterogeneity in the multiethnic sample to supplement the 
self-reported race/ethnicity data. The two SNPs were rs285 and rs2891, which were 
identified as AIMs in previous studies due to their largely different allele frequencies in 
major ancestral human populations [17,18]. Characteristics of each SNP are given in 
Table II. 
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Genotyping 
TaqMan allelic discrimination assay was the choice of method for genotyping. All 
SNPs were genotyped by TaqMan assays purchased from Life Technologies (Foster City, 
CA) on the Bio-Rad CFX96 real-time PCR instrument (Bio-Rad, Hercules, CA). The 
assay ID of each assay is given in Table II. 
Statistical analysis 
Genetic associations (both crude and adjusted) were evaluated by logistic 
regression using Stata v.11 (StataCorp, College Station, TX). Statistical interactions were 
also analyzed by logistic regression. All statistical tests were two-tailed and threshold for 
statistical significance was set at P≤0.05. All genetic associations, except the TFRC locus, 
were assessed by using the dominant genetic model which corresponds to variant allele 
positivity and coded as 1 for heterozygote and variant allele homozygote genotypes, and 
0 for the common allele homozygosity (referent). Due to the low frequency of their 
variant alleles, the two HFE SNPs were pooled together by creating a new variable for 
the number of cumulative variant alleles at both SNPs (0 for no variant allele, 1 for 
variant allele at either SNP, 2 for heterozygosity at both SNPs or variant allele 
homozygosity at either SNP (compound heterozygosity)). To be consistent with the 
previous studies, TFRC SNP was analyzed in recessive model (by coding variant allele 
homozygosity as 1 and the other genotypes as 0). A similar approach was used for a 
polygenic risk model using the total number of variant alleles at all five IRGs (0 for no 
variant allele at any SNP, 1 for one or two variant alleles at any SNP, 2 for three or more 
variant alleles at any of the five SNPs). All statistical associations in the overall group 
were adjusted for the race/ethnicity variable which had four categories (NHW, HW, 
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Blacks, and others). The efficiency of adjustment for race/ethnicity was double-checked 
by adjustment for each of the AIMs separately. Before proceeding to the statistical 
analysis of genetic associations, Hardy-Weinberg disequilibrium was ruled out in 
controls as a test for genotyping error. 
Results 
HFE C282Y and H63D frequencies in the sample population 
As expected, the HFE C282Y mutation was more common in the NHW subjects: 
variant allele frequencies were 0.113, 0.030 and 0.011 in NHWs, HWs, and Blacks, 
respectively. The H63D variant positivity also had similar variation across race groups 
with frequencies of 0.254, 0.151 and 0.032 in NHWs, HWs, and Blacks, respectively. 
Only two cases and two controls (all NHWs) were compound heterozygotes for HFE 
variants C282Y and H63D.  
Univariable genetic markers analyses 
Genotype frequencies for each SNP were in Hardy-Weinberg equilibrium in the 
control group when analyzed for each race/ethnicity group. All associations reported 
below for the whole group were adjusted for self-reported race/ethnicity. Replacing the 
race/ethnicity variable by either AIM did not appreciably alter the results. As shown in 
Table III, neither C282Y nor H63D showed an overall association with childhood ALL 
risk. The TFRC SNP, which was included in the study to assess its interaction with HFE 
SNPs did not show any individual association in the overall group. The two IRG variants 
selected as haplotype tagging SNPs for the respective promoter regions showed 
statistically significant associations in the overall analysis, but the association by the 
GWAS-identified marker for the iron levels did not reach statistical significance in the 
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overall analysis (Table III). This SNP only showed an association in males, as described 
below. 
Gender- and race/ethnicity-specific analyses and statistical interactions 
The differences in risk between genders were not significantly different, as judged 
by the statistical interaction test, but for the two TMPRSS6 SNPs, males had statistically 
significant risk associations (Table IV). Despite yielding greater ORs for males, the male-
specific HFE associations did not reach statistical significance in individual analysis. 
Results from pooling of the two HFE variants in one variable (as described in the 
methods) are shown in Figure I. The bars depict the risk genotype frequencies in the case 
and control groups, and ORs for childhood ALL risk are provided. The risk did not yield 
a statistically significant association in the overall group (OR = 1.46, P=0.17)(Graph A 
in Figure I), but the pooled variable was associated with a significant risk in males (OR = 
2.09, P = 0.04)(Graph B in Figure I), and even stronger when interacting with the TFRC 
variant (OR = 4.92, P = 0.002)(Graph D in Figure I). Graph C depicts the frequencies 
and OR for females cases/controls, and Graph E shows the frequencies and OR for males 
with the wild type allele for TFRC.  
There was no ethnicity-specific association of HFE variants. Ethnicity/race-
specific analyses revealed a strong risk association (OR = 2.54, CI: 1.05-6.12, P value = 
0.04) of the TFRC rs3817672 allele A homozygote genotype in NHWs, while the OR was 
less than 1.0 (non-significant) in Hispanics. The interaction of ethnicity and this TFRC 
genotype was statistically significant (Pinteraction = 0.02 for ethnicity). Thus, the only truly 
ethnicity-specific association with childhood ALL was the NHW-specific association of 
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TFRC. The strong association of the TMPRSS6 promoter region tagging SNP rs733655 
was equally strong in both major ethnicities examined in this study. 
We examined the TFRC and HFE gene-gene interactions previously observed in 
multiple cancers [1], including childhood ALL. In the overall sample, there was no 
interaction (data not shown). Our main group of interest was males because of the 
previous findings in childhood ALL, and also because of generally higher ORs in males 
in univariable analysis of HFE variants. Since the small sample size would not allow a 
reliable assessment of interactions for rare HFE variants, especially C282Y, we used the 
HFE pooled variant variable for this analysis. In the two groups of males with and 
without the TFRC homozygous genotypes, the ORs were 0.59 (CI = 0.24 to 1.45) and 
2.96 (CI = 1.29 to 6.80), yielding a statistically significant interaction (Pinteraction = 0.04). 
We also examined interactions of non-HFE SNPs with TFRC. This analysis did not 
reveal any interaction (P = 0.33, 0.46, and 0.96).  
Polygenic risk model 
We constructed a polygenic risk variable consisting of five IRG SNPs as 
described in the Methods section. Analysis using this variable showed that for stepwise 
increase in the number of variant alleles, there was a linear increase in childhood ALL 
risk in the overall group (OR = 1.63, 95% CI = 1.18 to 2.26, P = 0.003)(Figure II), and in 
males (OR = 2.00, 95% CI = 1.29 to 3.12, P = 0.002)(Figure II), but not in females (OR = 
1.26, 95% CI = 0.77 to 2.08, P = 0.36) in stratified analyses. In ethnicity-specific 
analysis, the association remained statistically significant in NHW (OR = 2.19, 95% CI = 
1.18 to 4.06, P = 0.01), but not in Hispanics (OR = 1.42, 95% CI = 0.89 to 2.27, P = 
0.14). 
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Discussion 
We examined previously reported HFE associations and interactions with TFRC 
with the risk of childhood ALL. In this multi-ethnic sample, we observed associations 
similar to previously reported ones with the same gender effect, and extended the 
observations to other iron regulatory gene polymorphisms to provide further support for 
our hypothesis that HFE and TFRC association in childhood ALL is due to their effect on 
iron homeostasis. The only statistically significant gender-specific associations with IRG 
variants and childhood ALL risk were in males, and we also noted a novel ethnicity-
specific association with the TFRC variant.  
Due to the limited sample size, we pooled the two HFE variants to increase 
statistical power to detect their associations with childhood ALL. The ORs for the pooled 
variables were always in the risk direction for individual SNPs, and were statistically 
significant in males. When the interaction with the TFRC genotype and the gender effect 
was considered, a more robust statistically significant association was found, as in a 
previous study [9]. The same interaction was also observed in multiple cancers without a 
gender effect [1,2]. While interaction analysis is usually seen as a challenge in terms of 
statistical power, as happened in the present study, the increase in the effect size may 
compensate for the loss of statistical power due to comparison of smaller subsets of the 
sample. Like any statistical association, our results should be considered cautiously. 
However, similarities with previous observations provide sufficient credibility to the 
cumulative results, which now strongly suggest that iron excess, whether 
environmentally- or genetically-induced increases the risk for cancer in general, and in 
particular childhood ALL. As previously postulated [9,19], the mechanism of the 
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childhood ALL risk association with HFE variants known to elevate body iron levels 
may include increased materno-fetal iron transport through placenta. This process is 
mediated by HFE and TFRC [20,21], and these genetically-mediated alterations in fetal 
iron homeostasis may also have implications on the developmental origins of health and 
disease [22].  
 Another novel finding of the present study was the risk associations of previously 
unexamined IRG SNPs (rs422982 and rs733655) with childhood ALL. Together with the 
association of rs855791, a GWAS identified marker for iron levels, which reached 
statistical significance only in males, these new findings lend support to our hypothesis 
that iron homeostasis related risk modification in childhood ALL extend beyond 
HFE/TFRC polymorphisms. We do not yet know whether the SNPs selected by us and 
used in any association study for the first time have any correlation with body iron levels. 
Their locations in crucial IRGs suggest that they will be somewhat involved in some 
aspect of gene function and subsequently in iron homeostasis, but only functional studies 
can confirm their roles. The lack of statistical interaction between these additional SNPs 
and the TFRC SNP suggested the specificity of the HFE and TFRC interaction. We were 
not surprised by the lack of interaction between SLC11A2 / TMPRSS6 and TFRC since 
they do not interact biologically. 
The present study highlights the benefits of explorations of effect modification by 
gender or ethnicity. Although such explorations are usually reserved for well powered 
studies, when backed up by previous observations or strong biological hypotheses, 
stratified analyses complemented by statistical interaction analyses are powerful 
approaches to unravel otherwise masked associations. It is only natural that in a 
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multigenic disorder like cancer, effect modification, which can be seen as multicausality, 
will be operational. Researchers usually shy away from analysis of effect modification or 
statistical interaction to avoid performing multiple comparisons and subsequent chance 
findings, but there are ways to rule out chance findings by additional replication studies.  
Besides the limitations already mentioned such as sample size and statistical 
power, our study has another limitation, which has stemmed from one of its strengths. 
Examination of these associations in a multi-ethnic cohort has benefits, but also brings 
about heterogeneity, which should be accounted for during analysis. We had self-reported 
race/ethnicity data, but adjustment of the results by these data may still leave some 
residual confounding. We also used two AIMs to make sure that the heterogeneity in the 
population will not result in spurious findings. The current practice in well-resourced 
GWAS studies is to use thousands of AIMs to adjust genetic ancestry, which is 
particularly crucial when the sample includes recently admixed populations such as 
African Americans or Hispanics. We could not do that, but could include a couple of 
AIMs to control for population heterogeneity. Another limitation of using a multi-ethnic 
sample was the constraints it adds on checking genotyping error. We followed the usual 
safeguards of genotyping error avoidance at the experimental phase, and checked for 
errors at the analysis phase by using Hardy-Weinberg equilibrium testing. This test, 
however, has to be done in each race/ethnicity subgroup separately. This practice further 
reduces the statistical power of this test and may have caused inefficiency of genotyping 
error checking. Genotyping errors have the potential to cause both false positives and 
false negatives. Our results basically replicated previously observed associations, and 
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there is no overwhelming reason to consider genotyping errors as an alternative 
explanation.  
By replicating the HFE and TFRC interaction in childhood ALL risk association 
and revealing new associations with IRGs, our study provided further evidence for the 
hypothesis on the iron connection in childhood ALL susceptibility. These findings have 
far reaching implications beyond childhood leukemia in the cancer field. We hope that 
our results will stimulate interest in secondary analyses of existing GWAS data on 
multiple cancers to explore the pathways involved in iron homeostasis. We also report 
novel associations with gender or ethnicity specificity. These associations can also be 
replicated using already existing datasets. Since no childhood ALL GWAS dataset is 
currently available through public databases, we could not try replication, but we hope to 
be able to do so in the future as databases become available for additional analysis. 
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Table I. Characteristics of cases and controls  
 
  Cases  n=161 
Controls 
n=231 P value 
Ethnic background  
  Non-Hispanic White 
  Hispanic White 
  Black 
  Other* 
 
66 
72 
17 
6 
 
49 
98 
78 
6 
<0.001 
Gender 
  Male 
  Female 
  Ratio 
 
86 
75 
1.15 
 
130 
101 
1.29 
0.58 
 
*Asian, Native American, or other 
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Table II. Main features of SNPs analyzed 
 
*Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide position (http://www.ncbi.nlm.nih.gov/SNP/) 
†Minor allele frequencies are from a reference Caucasian population (U.S. residents of northern and western European ancestry) genotyped in HapMap 
project 
Gene SNP Chromosome nucleotide position* 
Minor allele and 
frequency† SNP Type Assay ID 
HFE rs1800562 chr6: 26093141 (A) 0.053  Transition substitution, missense mutation C___1085595_10 
HFE rs1799945 chr6: 26091179 (G) 0.179  Missense mutation, transversion substitution C___1085600_10 
TFRC rs3817672 chr3: 195800811 (G) 0.383  Transition substitution, missense mutation C___3259537_10 
SLC11A1 rs422982 chr12: 51406354 (A) 0.246  Transversion substitution, intragenic C____570333_10 
TMPRSS6 rs733655 chr22: 37495051 (C) 0.221  Transition substitution, intragenic C___3289858_1_ 
TMPRSS6 rs855791 chr22: 37462936 (T) 0.412  Transition substitution, missense mutation C___3289902_10 
LPL rs285 chr8: 19815189 (T) 0.500  Transition substitution, intragenic C__12104266_10 
ITGAE rs2891 chr17: 3705526 (G) 0.496  Transition substitution, intragenic C___3211308_20 
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Table III. Univariable analyses of associations with childhood ALL risk* 
 
SNP OR (95% CI) P value 
HFE rs1800562 1.37 
(0.52 to 3.60) 
0.52 
HFE rs1799945 
1.33 
(0.74 to 2.38) 
0.35 
TFRC rs3817672 0.8 
(0.52 to 1.23) 
0.31 
SLC11A2 rs422982 
1.55 
(1.01 to 2.37) 
0.04 
TMPRSS6 rs733655 2.06 
(1.33 to 3.20) 
0.001 
TMPRSS6 rs855791 
1.41 
(0.91 to 2.18) 
0.12 
 
*Adjusted for self-reported ethnicity and race (non-Hispanic White, Hispanic White, Blacks and others) 
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Table IV. HFE and non-HFE associations with childhood ALL in gender and 
race/ethnicity groups (ORs and 95% CIs) 
 
  Females Males Non-Hispanic Whites Hispanic Whites 
HFE rs1800562 0.4 3.41 1.78 0.91 
  Pinteraction = 0.09 Pinteraction = 0.55 
HFE rs1799945 1.01 1.51 1.26 0.87 
  Pinteraction = 0.78 Pinteraction = 0.56 
TFRC rs3817672 1.66 0.7 
2.54 
(1.05 to 6.12) 
P = 0.04 
0.69 
  Pinteraction = 0.21 Pinteraction = 0.02 
SLC11A2 rs422982 1.58 1.52 1.47 1.91 (0.99 to 3.68) 
  Pinteraction = 1.00 Pinteraction = 0.61 
TMPRSS6 rs733655 1.56 
2.6 
(1.44 to 4.70) 
P = 0.002 
2.35 
(1.07 to 5.16) 
P = 0.03 
2.52 
(1.26 to 5.04) 
P = 0.009 
  Pinteraction = 0.19 Pinteraction = 0.90 
TMPRSS6 rs855791 1.12 
1.91 
(1.04 to 3.51) 
P = 0.04 
1.71 1.22 
  Pinteraction = 0.40 Pinteraction = 0.52 
 
*Adjusted for self-reported ethnicity and race (non-Hispanic White, Hispanic White, Blacks and others).  
 P values for individual analyses are only shown when <0.05
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Figure I. Risk genotype frequencies with pooled HFE association in childhood ALL in case and control groups, by 
gender and TFRC genotype group
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0 = no variants, 1 = one or two variants, 2 = three+ variants 
 
Figure II. Polygenic risk variable consisting of five IRG SNPs and childhood ALL risk
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CHAPTER VI 
 
BIRTH CHARACTERISTICS AND CHILDHOOD LEUKEMIA RISK: 
CORRELATIONS WITH GENETIC MARKERS 
 
Abstract  
Birth characteristics such as birth order, birth weight, birth defects, and Down 
syndrome showed some of the first risk associations with childhood leukemia. Besides 
these non-genetic factors, recent genetic association studies have also identified markers 
for susceptibility. Examinations of correlations between birth characteristics and 
leukemia risk markers have been limited to birth weight-related genetic polymorphisms. 
We aimed to revisit associations of birth characteristics with childhood acute 
lymphoblastic leukemia (ALL) as well as their correlations with selected ALL risk 
markers to integrate information on non-genetic and genetic markers.  The study sample 
was multi-ethnic/racial consisting of cases with childhood (≤18yr) ALL (n=161) and 
healthy controls (n=261) recruited contemporaneously between 2007 and 2012. Non-
genetic data on birth weight, birth length, and gestational age were collected through 
administration of questionnaires, and genetic markers were genotyped using TaqMan 
allelic discrimination assays. We observed risk associations for having a birth weight of 
over 4,000 grams compared with being less than 4,000 grams (OR = 1.93, 95% CI = 1.16 
to 3.19, P = 0.01), birth length (OR = 1.18 per inch, 95% CI = 1.01 to 1.38, P = 0.04), 
and with gestational age (OR = 1.10 per week, 95% CI = 1.00 to 1.21, P = 0.04). None of 
the associations interacted with gender or ethnicity. When we examined correlations 
between these birth characteristics and genetic markers, only the HFE tagging SNP 
rs9366637 showed an inverse correlation with gestational age with a gene-dosage effect 
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(P = 0.005) and in interaction with a transferrin receptor (TFRC) rs3817672 genotype 
(Pinteraction =  0.05). This correlation was translated into a strong association for this SNP 
with preterm birth (gestational age ≤ 37 weeks) with five of ten subjects born preterm 
being positive for the variant allele of rs9366637 (OR = 5.0, 95% CI = 1.19 to 20.9, P = 
0.03). The strong interaction with TFRC suggests that rs9366637 may be involved in the 
modification of HFE-mediated placental iron transfer. Our study provides evidence for 
the involvement of prenatal events in the development of childhood ALL. The inverse 
correlation of HFE rs9366637 with gestational age has implications on the design of HFE 
association studies in birth weight and childhood conditions using full-term newborns as 
controls. If this statistical association is confirmed and its biological mechanisms include 
iron homeostasis changes, as suggested by our findings, the use of iron supplementation 
during pregnancy may need to be more targeted. 
Introduction  
Birth order, birth weight, birth defects, and Down syndrome were among the first 
risk factors shown to be associated with childhood leukemia risk [1-3]. Subsequent 
studies have established Down syndrome, increased birth weight, and several congenital 
disorders as consistent risk factors for childhood acute lymphoblastic leukemia (ALL) 
[4,5]. More limited data are available on the suggestive associations of being first-born, 
maternal age and miscarriages in maternal reproductive history with childhood ALL [5]. 
Of these, only the molecular mechanism of Down syndrome association has been 
established [6]. Birth weight shows a consistent positive association with childhood ALL 
that has been confirmed by meta-analyses [7-9]. Several biological mechanisms for the 
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birth weight association have been speculated [10-12], but none have been established 
firmly. 
Although a number of studies have examined the associations of birth 
characteristics with childhood ALL [10,13-20] and adult cancer risk [21], few examined 
the correlations between genetic risk markers and birth characteristics, mainly birth 
weight [22]. Those studies that did examine genetic risk factors used polymorphisms 
previously identified in genome-wide association studies (GWAS) and mostly yielded 
negative results. The importance of the examination of birth characteristics in childhood 
ALL research stems from recent evidence suggesting a prenatal origin for childhood ALL 
development [23-26], and more broadly the concept of developmental origins of health 
and disease [27-29].  
Our aim was to examine associations of birth characteristics with childhood ALL 
as well as their correlations with selected risk markers for childhood ALL to integrate 
information on non-genetic and genetic markers. We had data on birth weight, birth 
length, and gestational age, and we included a representative set of risk markers 
previously identified in GWAS, HLA region markers due to the association of HLA 
region polymorphisms with birth weight [30-33], iron regulatory gene HFE 
polymorphisms previously shown to correlate with birth weight [11] and additional iron-
regulatory genes for their potential associations with birth characteristics. Since our 
sample was multi-ethnic/racial, we also explored heterogeneity among non-Hispanic 
Whites and Hispanics in any association observed. 
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Subjects & Methods  
Subjects 
Institutional Review Board (IRB) approval was received at the Baylor College of 
Medicine (BCM) and Florida International University prior to the start of the research 
project. Subjects were recruited at Texas Children’s Hospital in Houston, TX. The study 
was originally designed as a leukemia association study. The case-control group 
consisted of 161 incident childhood ALL cases and 231 healthy age-matched controls 
contemporaneously recruited at Texas Children’s Hospital general pediatrics clinics. The 
children were less than 18 years of age at diagnosis, and exclusion criteria for both 
groups included refusal to participate in the study and the diagnosis of any other disease 
or cancer. Subjects and their parents were approached to acquire informed consent and 
epidemiological data with a questionnaire and a biological sample, thus the gestational 
age data was not record-based. DNA samples were obtained from either saliva or 
peripheral blood samples at Texas Children’s Hospital. Parents were asked to provide 
race (White, Black/African American, Asian, American Indian/Alaska Native, or Native 
Hawaiian/Other Pacific Islander) and ethnicity (Hispanic/Latino or non-Hispanic/Latino) 
of the child.  
Genotyping 
Genotyping was completed on the Bio-Rad CFX96 real-time PCR machine 
(Hercules, CA) using Life Technologies TaqMan® single nucleotide polymorphism 
(SNP) genotyping assays (LifeTech, Foster City, CA). The singleplex reactions were 
carried out in 96-well plates and used Bio-Rad’s SsoFast™ Probes Supermix as the 
reaction buffer. PCR amplifications were performed using the manufacturer’s suggestion 
85 
 
of total volume/well and PCR thermal cycling conditions. SNPs of interest are listed in 
Table I together with their features. SNPs included were: established ALL risk markers in 
previous GWAS, HFE SNPs known to correlate with body iron levels, another IRG SNP 
that shows a very high correlation with serum iron parameters in GWAS, and two 
additional IRG SNPs selected by us as haplotype tagging SNPs for the promoter regions 
of two IRGs. We also included three HLA region SNPs known to modify lymphoma risk, 
one being the marker for the HLA-DRB4 lineage [34], which is also associated with risk 
for major leukemia types, as previously shown in candidate gene studies [35-39]. Two 
additional SNPs (rs285 and rs2891) were included as ancestry informative markers 
(AIMs) for statistical adjustment of ethnicity and race as has been used in Hispanic 
populations to account for the differences in genetic ancestry [40,41]. Bio-Rad CFX 
Manager software (version 3.0) was used for data acquisition and genotype assignment. 
Statistical analysis 
Statistical analyses were performed using Stata v.11 (StataCorp, College Station, 
TX, USA). Logistic regression was used to explore the associations of birth 
characteristics (birth weight, birth length, gestational age) with childhood ALL risk. 
Linear regression was used to assess correlation of genetic markers with continuous birth 
characteristic variables. The threshold for statistical significance was set at P ≤ 0.05, and 
95% confidence intervals (CI) of odds ratios (OR) were computed. Pearson’s Χ2, 
Student's t-test (for means) or median test (for medians) were used to compare 
characteristics between the case and control groups. Genotype counts were tested for 
Hardy–Weinberg equilibrium (HWE) in controls for each SNP. Correlations with genetic 
markers were assessed using the dominant model in which polymorphic allele carrying 
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genotypes are coded as 1 and the wildtype (common allele homozygote) genotype is 
coded as 0. When a SNP association was found, gene-dosage effect was explored by 
using the additive genetic model which uses all three genotypes coded as 0, 1 and 2 
reflecting the number of polymorphic alleles present in the genotype. For most analyses, 
cases and controls were pooled to increase statistical power, but only after ruling out 
heterogeneity. As the sample was heterogeneous in its ethnic/racial composition, and 
genetic markers show variation in these groups, all results are adjusted for self-declared 
ethnic/racial groups (coded as non-Hispanic Whites, Hispanic Whites, Blacks and 
others). To rule out residual confounding, two SNPs were also used for adjustments, 
individually, to check whether the results were changed after adjustment for genetic 
ancestry.  
Results  
Characteristics of the case-control sample are shown in Table II. The case 
samples included 86 males (53%) and 75 females (47%). Out of the cases, 66 identified 
themselves as non-Hispanic White (NHW), 72 as Hispanic White (HW), 17 as Black, and 
6 as “other.” The “other” group included those identifying themselves as Asian, Native 
American, or other. The controls included 130 males (56%) and 101 females (44%), who 
had visited the pediatric clinic for a non-disease related reason. Forty-nine were classified 
as NHW, 98 as HW, and 78 as Black. The distribution of race and ethnic background was 
different between cases and controls, mainly due to the infrequency of childhood ALL in 
Blacks. Because of this difference, results were adjusted for racial/ethnic background or 
stratified analyses were performed when necessary. The differences in birth 
characteristics between cases and controls are detailed below.  
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Birth weight  
There was no association between childhood ALL and birth weight when the birth 
weight variable was retained as a continuous variable. Since most studies reported a risk 
association with birth weight of 4,000 grams or higher, we categorized the variable as 
high birth weight (≥4,000g) - others (<4,000g), and re-examined the association. There 
was a statistically significant association with high birth weight in the overall group (OR 
= 1.93, 95% CI = 1.16 to 3.19, P = 0.01, adjusted for self-declared ethnicity/race). 
Although there was no statistical interaction with gender or ethnicity, among the 
subgroups, the association reached statistical significance in males and in Hispanics. The 
OR was as high as 3.18 (95% CI = 1.16 to 8.73, P = 0.02) in Hispanic males. The overall 
association with high birth weight did not change when adjusted for each AIM instead of 
self-declared ethnicity/race. The association with birth weight could not be attributed to 
gestational age heterogeneity, and adjustment for gestational age or restriction of the 
analysis to subjects born at or later than 38 weeks of gestational age did not result in a 
substantial change in the OR of the association. By categorizing the birth weight variable 
into three groups (<2500g; 2500-3999g; ≥4000g), the overall association and association 
in males remained statistically significant (data not shown).  
Birth length  
As a continuous variable, birth length showed an overall association with 
childhood ALL risk (OR = 1.18 per inch, 95% CI = 1.01 to 1.38, P = 0.04). Among the 
subgroups, this association was statistically significant in females and in non-Hispanic 
Whites, but there was no statistical interaction with gender or ethnicity. In non-Hispanic 
White females, the OR was 1.81 (95% CI = 1.03 to 3.18, P = 0.04). Restricting the 
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analysis to subjects born at gestational age 39 week or later (full-term) did not weaken 
the results. On the contrary, the OR in the whole group became 1.25, and 3.03 in non-
Hispanic females, both remaining statistically significant.   
Gestational age  
In the overall group, there was a risk association with gestational age (OR = 1.10 
per week, 95% CI = 1.00 to 1.21, P = 0.04, adjusted for ethnicity/race). This association 
did not interact with gender or ethnicity/race although it was stronger in females and in 
Hispanics with the OR reaching 1.43 (95% CI = 1.09 to 1.87, P = 0.009). Categorization 
of the gestational age variable into three groups (<38 wk; 38wk; >38wk) resulted in the 
loss of statistical significance for the association.   
Correlation of birth characteristics with genetic markers  
Having found associations between birth characteristics and childhood ALL risk, 
we sought correlations between the birth characteristics and SNPs included in this study. 
For these analyses, the birth weight variable was used as high birth weight (≥4,000g) 
versus others; and birth length and gestational age variables were used as continuous 
variables. Correlations were sought in the whole group as well as in the subgroup that 
showed the strongest leukemia association. We were able to show a correlation for only 
one genetic marker and gestational age. HFE tagging SNP rs9366637 showed a 
significant negative correlation with a gene-dosage effect (P=0.005) with gestational age. 
Males had a stronger negative correlation (P=0.001) with this variant. There was no 
association in females (P=0.98), and the interaction with gender reached statistical 
significance (Pinteraction=0.02 for gender). No heterogeneity was found when analyzing the 
case and control groups separately. In fact, the regression coefficients were larger in the 
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control group. Replacing the self-declared ethnicity/race variable with either AIM for 
adjustment did not alter the results. The average gestational age showed a stepwise 
change with increasing number of rs9366637 variant alleles, with the mean gestational 
age decreasing from 38.6 weeks (homozygous wild-type) to 36.7 weeks (homozygous 
variant) (Figure I, Graph A). 
Because of the known biological relationship between HFE and TFRC, rs3817672 
was genotyped, and the interaction between rs3817672 and rs9366637 variant alleles was 
assessed. There was a significant statistical interaction between them (Pinteraction=0.02). 
Overall, the negative association between rs9366637 and decreasing gestational age 
increased in statistical significance (P=0.001), and the male subgroup again showed the 
strongest negative correlation (P<0.001) in subjects with the particular TFRC genotype. 
Figure I depicts the mean gestational age by HFE rs9366637 and TFRC rs3817672 
genotypes. Bar graph A in Figure I shows the gestational age means for just the HFE 
variant on its own, in the overall group. Graphs B and C depict the gestational age means 
for the HFE variant depending on the TFRC genotype (AA in Graph B and AG/GG 
combined in Graph C). Lastly, bar graphs D and E show the mean gestational age for 
males (D) and females (E) who had the HFE and TRFC genotypes that jointly showed the 
strongest correlation with gestational age (Pinteraction = 0.001).  
We also examined the association of the HFE SNP rs9366637 with preterm birth 
defined as gestational age less than 37 weeks. Despite very small number of preterm 
births in the overall sample (n=65), there was an association between this SNP and 
preterm birth in non-Hispanic White males (P = 0.03), which was due to five of ten 
preterm males being positive for the variant allele of rs9366637.  
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Discussion  
This study observed a birth weight association with childhood ALL risk [7-9], and 
novel associations with birth length and gestational age. While birth length association 
may be due to similar mechanisms as the birth weight association, the gestational age 
association is novel. The birth weight association is well known in childhood ALL, and 
fetal growth rate is probably even more crucial [9], but we were not able to assess fetal 
growth rate due to sample size limitations. Another novel finding was the inverse 
correlation between an HFE SNP and gestational age. This association showed gender-
specificity, gene-dosage effect and a statistical interaction with another genotype that has 
biological basis. This is a novel finding worth pursuing in future research, as it may lead 
to development of a marker with some clinical utility.  
The HFE SNP rs9366637 (IVS1) has not been studied as extensively as the other 
HFE variants rs1800562 (C282Y) or rs1799945 (H63D), and has not been directly 
implicated in iron regulation. It has shown a weak correlation with birth weight [11] and 
a strong association with adult height [42]. In a case-control study in a Han Chinese 
sample, the variant allele for rs9366637 was also found to be a significant risk marker for 
coronary heart disease (CHD) [43]. The haplotype tagged by this SNP is always devoid 
of the two variants C282Y and H63D that are associated with increased iron levels and 
presumably increased iron placental transfer. Since rs9366637 is a tagging SNP, we 
explored polymorphisms tagged by rs9366637 to see if any were functional and/or 
previously assessed (Table III). We were not able to attribute any functionality to any of 
the tagged SNPs for which rs9366637 is a proxy, nor was there any published disease 
associations with any of these SNPs.  
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The inverse correlation found between rs9366637 and gestational age, and its 
interaction with TFRC brings speculation on whether this SNP is also involved in iron 
homeostasis. There is no known effect with this SNP on HFE function, but being positive 
for this SNP would assure the lack of H63D or C282Y on the same chromosome 
negatively affecting placental iron transfer. Thus, if the association of rs9366637 is due to 
its modification of HFE function, it is more likely to be not facilitating iron transfer into 
the developing fetus.  
The risk association of rs9366627 and CHD in a Han Chinese population where 
the minor allele frequency is much higher than in European populations may be 
consistent with its association with preterm birth [43]. Babies born before term are also 
low birth weight and at high risk for cardiovascular diseases later in life [27]. This issue 
has been recently revisited and nutrition of preterm babies with special formula and 
accelerated growth in very early life have been considered in the pathogenesis of later 
development of disease in preterm babies [44]. It is important to note that rs9366637 is 
also associated with body height in adults [42], and may predispose babies to accelerated 
growth. Although our findings are purely statistical correlations, future studies should 
explore potential implications of these findings. 
 We included the interaction analysis of the TFRC variant rs3817672 with HFE 
variant rs9366637 to see if a gene-gene interaction existed. The presence of the TFRC 
“A” allele was associated with increased risk for preterm birth in rs9366637 variant-
positive individuals, specifically males. Interactions between HFE and TFRC allele “G” 
have also been noticed in various cancers, including multiple myeloma, breast, and 
colorectal cancer [45] as well as childhood ALL [11]. Since the HFE interaction with 
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TFRC allele G is believed to increase iron transport leading to increased birth weight [11] 
and cancer risk [46], it is important to note that the interaction of rs9366637 was with 
TFRC allele A in its association with shorter gestational age. This contrast suggests that 
the inverse correlation with gestational age, if causal, is likely to be due to insufficient 
iron transfer to the fetus. Iron deficiency is indeed a known risk factor for preterm birth 
[47]. 
 There were important limitations with our study, including sample size. We were 
able to pool the cases and controls (n=392) to gain statistical power, since cases and 
controls did not show statistical heterogeneity for the correlation with the HFE SNP. 
Gestational age was provided by the mother of the child enrolled in the study through a 
questionnaire. Previous studies, however, have shown a high correlation between birth 
weight, gestational ages, and other birth characteristics provided by the mother of a 
patient and medical chart recordings [17, 48]. Non-differential measurement error may 
have occurred, causing towards-the-null bias, if not all gestational ages were correctly 
recalled. Missing data was another limitation in our study, with 88% of the total group 
having gestational age data.  
Results from this study raise an important issue in study designs for future 
childhood studies. Most studies of a childhood disease consist of a control group 
comprised of full term babies and include as many cases as possible, regardless of their 
birth term. By doing this, the control group could be missing a whole group of children 
who may be carriers of certain variant genetic markers. Variants that may be associated 
with non-term births would be eliminated from the control group. The outcome of this 
mistake could lead to spurious results. 
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 In conclusion, the HFE variant rs9366637 has shown a statistically significant 
negative correlation with gestational age. The SNP rs9366637, which is not known to be 
involved with iron homeostasis, showed a positive interaction with a TRFC genotype and 
yielded a stronger association with shorter gestational age, specifically in males. This 
correlation may reveal a connection between altered placental iron transfer and the risk of 
preterm birth. Since our study did not observe other correlations between a number of 
genetic markers and birth characteristics investigated, this may be another area that needs 
to be addressed in larger and more comprehensive studies, ideally using a GWAS design. 
If our results are validated in different populations, the findings will have implications on 
iron supplementation strategies during pregnancy.  
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Table I. Main features of SNPs analyzed 
Gene SNP Chromosome nucleotide position* 
Minor allele and 
frequency** SNP Type 
HFE rs1800562 chr6: 26093141 (A) 0.053  Transition substitution, mis-sense mutation 
HFE rs1799945 chr6: 26091179 (G) 0.179  Mis-sense mutation, transversion substitution 
HFE rs9366637 chr6: 26089098 (T) 0.064 Intronic; transition substitution 
TFRC rs3817672 chr3: 195800811 (G) 0.383  Transition substitution, mis-sense mutation 
SLC11A1 rs422982 chr12: 51406354 (A) 0.246  Transversion substitution, intragenic 
TMPRSS6 rs733655 chr22: 37495051 (C) 0.221  Transition substitution, intragenic 
TMPRSS6 rs855791 chr22: 37462936 (T) 0.412  Transition substitution, mis-sense mutation 
ARID5B rs7089424 chr10: 63752159 (G) 0.314 Intronic 
ARID5B rs10821936 chr10: 63723577 (C) 0.318 Intronic 
ARID5B rs10994982 chr10: 63710104 (A) 0.457 Intronic 
IKZF1 rs4132601 chr7: 50470604 (G) 0.306 3'-UTR 
CEBPE rs2239633 chr14: 23589057 (A) 0.466 5'-upstream 
HLA-DR region rs2395185 chr6: 32433167 (T) 0.423 Intronic 
HLA-DQB1 region rs2647012 chr6: 32664458 (T) 0.381 Intergenic 
HLA-DQA1 region rs10484561 chr6: 32665420 (G) 0.084 Intergenic 
LPL rs285 chr8: 19815189 (T) 0.500  Transition substitution, intragenic 
ITGAE rs2891 chr17: 3705526 (G) 0.496  Transition substitution, intragenic 
 
*Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide position (http://www.ncbi.nlm.nih.gov/SNP/) 
 
**Minor allele frequencies are from a reference Caucasian population (U.S. residents of northern and western European ancestry) genotyped in HapMap 
project 
†† IVS1: intervening sequence 1 SNP 
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Table II. Characteristics of cases and controls 
  Cases  n=161 
Controls 
n=231 P value 
Ethnic background  
  Non-Hispanic White 
  Hispanic White 
  Black 
  Other* 
 
66 
72 
17 
6 
 
49 
98 
78 
6 
<0.001 
Gender 
  Male 
  Female 
       Ratio 
 
86 
75 
1.15 
 
130 
101 
1.29 
0.58 
Birth weight (grams) 
  Mean (SD) 
  Median (IQR) 
 
3349.3 (584) 
3400 (760) 
 
3263.3 (684) 
3311.5 (850) 
 
0.23 
0.48 
Gestational age (weeks) (SD) 38.8 (2.2) 38.2 (2.8) 0.04 
Birth length (cm) (SD) 51.4 (3.4) 50.1 (5.05) 0.024 
 
*Asian, Native American, or other 
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Table III. HFE rs9366637 and its tagging SNPs 
 
Proxy Distance r2* Chr. Nucleotide number SNP Location 
rs9366637 0 1.000 6 26089098 Intronic 
rs2050947 19019   1.000 6 26070079 Intergenic 
rs9295682 19604   1.000 6 26069494 Intronic 
rs9379826 23058   0.892 6 26112156 Intergenic 
rs9393682 32048   0.892 6 26165029 Intergenic 
 
*An indication of the correlation with rs9366637; scale of 0-1 with 1 denoting maximum correlation 
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Figure I. Gene-gene and gene-gene-gender interactions in gestational age association of HFE rs9366637
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CHAPTER VII 
CONCLUSIONS AND FUTURE RESEARCH 
Conclusions 
This dissertation research was conducted to explore the correlations among 
genetic polymorphisms, birth characteristics, and the risk of childhood ALL. The 
replication of GWAS childhood leukemia markers [1,2] validated our case-control group 
and added credibility to the results of our present project. The genotyping of HLA region 
lymphoma risk markers not only confirmed a previous male-only strong risk association 
from rs2395185 [3], but also identified new risk markers for childhood ALL. All 
significant associations with lymphoma risk markers were in opposite risk direction 
compared to the lymphoma association studies. HLA region marker rs2647012 was found 
to be a significant risk only in Hispanics, and rs1048456, a risk marker in follicular 
lymphoma showed a statistically significant protective association.   
 Our hypothesis that iron-regulatory gene (IRG) variants known to elevate iron 
levels increase childhood ALL risk was driven by previous research, which showed a 
male-specific childhood ALL risk [4-6], and the biological implications showing iron 
excess associated with other cancers [7-11]. We examined the effect modification by 
gender and race/ethnicity in childhood ALL susceptibility, and also looked into gene-
gene interactions to test our hypotheses. 
  The main objective of re-examining the association with HFE variants and 
childhood ALL susceptibility was accomplished. Our results not only replicated previous 
HFE risk associations with childhood ALL [4,5], but by extending similar findings to 
other IRG SNPs, strengthened the hypothesis that iron excess mediated by genetic 
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variants contributes to childhood ALL risk. It was previously known that HFE variants 
that correlate with body iron levels show associations with cancer risk, including 
childhood ALL [4,5], and also show a correlation with birth weight. Our results 
confirmed this leukemia risk, with replication of the male-only association [4,5].  
Birth characteristics such as birth weight, height, and gestational age were 
examined to see if correlations with childhood ALL existed. Birth length showed an 
overall risk association with childhood ALL, with females and non-Hispanic Whites 
showing significance among the subgroups. There was no statistical interaction with 
gender or ethnicity, however. The correlation between birth weight and childhood ALL 
[12,13]  was evident when comparing those having a birth weight of over 4,000 grams 
with those less than 4,000 grams.  No individual SNP showed a correlation with birth 
length or birth weight.  A novel significant risk association with gestational age overall 
did not interact with gender or ethnicity/race, although it was stronger in females and in 
Hispanics. 
Correlations between HFE SNPs and gestational age were also examined. A 
significant negative correlation was found with the HFE variant rs9366637, more 
robustly among males. The inverse correlation of rs9366637 with gestational age has 
implications on the design of HFE association studies in birth weight and childhood 
conditions using newborns as controls.  
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Future Research 
 As with any epidemiological study, and especially important with genetic 
association studies, there is a need for replication and follow up studies to ensure the 
findings are valid [14-16]. Our conclusions are based on statistical correlations, therefore 
properly executed genetic and functional replication studies are necessary. Proper study 
design addressing the sample size issue for a rare disease like childhood ALL is crucial in 
follow up studies. 
 Our conclusions require independent replications done properly; meaning the 
methods of analysis should be consistent. A recent publication failed to replicate the HFE 
variant risk association with childhood ALL [17]. The researchers did not take into 
account gender effect and gene-gene interactions that are stated in the parent study, 
therefore the results are not a true replication failure of the original study. 
 The only way to confirm our hypotheses would be to examine pre-diagnostic iron 
levels, making cohort studies a necessity. Even as unrealistic and unfeasible as it may 
seem because childhood ALL is such a rare disease, ideally a cohort study would be best 
for this research. Any replication should be done in an international collaboration format 
as well, so that the sample size is increased, therefore statistical power for more robust 
and credible results would also increase. Both of these criteria are achievable because of 
the Childhood Leukemia International Consortium (CLIC), a giant international 
consortium that pools data from independent studies from 12 countries across the world 
[18].  
 Our research is significant in terms of both population health and in scientific 
advancements. Results may indicate a possible biological mechanism of the role iron 
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plays in the cancer association, leading to an impact on both child and maternal health. 
Educating the public on lifestyle modifications for preventive measures, such as 
controlled iron supplementation during pregnancy, unregulated access to iron-containing 
multivitamins, and avoidance from the unnecessary consumption of iron-rich food, could 
reduce the risk of leukemia in children.  
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